

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Atherogenic dyslipidemia and prognosis in coronary artery disease patients with pre-diabetes and diabetes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037340
Article Type:	Original research
Date Submitted by the Author:	30-Jan-2020
Complete List of Authors:	<p>Gao, Ying; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Jin, Jing-Lu; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Cao, Ye-Xuan; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Wu, Li-Guo; TangXian Peoples Hospital, Hebei Province</p> <p>You, Xiang-Dong; TangXian Peoples Hospital, Hebei Province</p> <p>Guo, Na; TangXian Peoples Hospital, Hebei Province</p> <p>Guo, Yuan-Lin; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Wu, Na-Qiong; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Zhu, Cheng-Gang ; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Xu, Rui-Xia; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Liu, Hui-Hui; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia</p> <p>Sun, Jing; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Dong, Qian; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Li, Jian-Jun; Chinese Academy of Medical Science, Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p>
Keywords:	Lipid disorders < DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, Coronary heart disease < CARDIOLOGY

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**BMJ Open****2020-01-29**

**Title:** Atherogenic dyslipidemia and prognosis in coronary artery disease patients with pre-diabetes and diabetes

**Running Title:** lipid, glucose and outcomes

**Authors:** Ying Gao<sup>1\*</sup>, MD; Jing-Lu Jin<sup>1\*</sup>, MD; Ye-Xuan Cao<sup>1</sup>, MD; Li-Guo Wu<sup>2</sup>, MD; Xiang-Dong You<sup>2</sup>, MD; Na Guo<sup>2</sup>, MD; Yuan-Lin Guo<sup>1</sup>, MD; Na-Qiong Wu<sup>1</sup>; MD, Cheng-Gang Zhu<sup>1</sup>; MD, Rui-Xia Xu, PhD; Hui-Hui Liu,<sup>1</sup> MD; Jing Sun<sup>1</sup>, MS; Qian Dong<sup>1</sup>, MS; Jian-Jun Li<sup>1\*</sup>, MD, PhD

The first two authors contributed equally

**Address:** 1. State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China. 2. TangXian Peoples Hospital, Hebei Province, 072350, China.

**\*Correspondence:** Professor Jian-Jun Li, MD, PhD. BeiLiShi Road 167, Beijing 100037, China

**Tel:** 86+10+88396077; **Fax:** 86+10+88396584;

**E-mail:** lijianjun938@126.com

**ORCID:** 0000-0003-2536-4364

## Abstract

**Objective:** The aim of the study is to investigate the impacts of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) dyslipidemia on prognosis in coronary artery disease patients with different glucose metabolism status.

**Design:** An observational cohort study

**Setting/Participants:** A total of 3057 patients with stable coronary artery disease (CAD) were consecutively enrolled and divided into 3 groups according to different glucose metabolism

p presented 1.441-fold higher risk of CVEs (HR:1.44, 95%CI: 1.02-2.04). Wstatus [diabetes mellitus (DM), pre-diabetes mellitus (Pre-DM), normal glycaemia regulation (NGR)]. Atherogenic dyslipidemia (AD) was defined as TG $\geq$ 1.7mmol/L and HDL-C $<$ 1.0mmol/L for man or  $<$ 1.3mmol/L for women. These patients were further classified into 6 subgroups by status of atherogenic dyslipidemia. All subjects were followed up for the cardiovascular events (CVEs).

**Primary outcome measure:** The primary endpoints (CVEs) were cardiovascular mortality, non-fatal myocardial infarction (MI) and stroke.

**Results:** During a median follow-up of 6.1 years, 308 (10.1%) CVEs occurred. No significant difference in occurrence of CVEs was observed between NGR and Pre-DM groups [Hazard Ratio (HR): 1.252, 95% confidence interval (CI): 0.89-1.76] while DM grouhen the participants were categorized according to combined status of two parameters, the cardiovascular risk was significantly elevated in Pre-DM or DM plus AD group compared with the NGR plus Non-AD group (HR: 1.62, 95%CI: 1.06-2.46 and HR: 1.81, 95%CI: 1.13-2.91).

**Conclusions:** The present study firstly showed that the presence of atherogenic dyslipidemia had a significant impact on CVEs in Pre-DM.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** triglyceride, HDL-C, pre-diabetes, prognosis

For peer review only

## Strengths and limitations of this study

- This study firstly indicated that the presence of atherogenic dyslipidemia had a significant impact on cardiovascular outcome in patients with pre-diabetes mellitus (Pre-DM)
- In the current study, hard endpoints containing nonfatal strokes, nonfatal myocardial infarction, and cardiovascular mortality were observed during a relatively long follow-up period.
- The levels of triglyceride and high-density lipoprotein cholesterol were measured only at the baseline.
- We did not assess the all metabolic factors and parameters about insulin resistance due to the features of patients in our study.



## Introduction

Dyslipidemia is one of the key drivers in atherogenesis. Lipid lowering therapy targeting at low density lipoprotein cholesterol (LDL-C) has been proved to be efficient in decreasing the progression of arteriosclerotic cardiovascular disease (ASCVD) [1]. Moreover, strong evidence in epidemiological, genetic and prospective cohort studies verifies that high triglyceride (TG) and/or low levels of high density lipoprotein cholesterol (HDL-C) are associated with cardiovascular disease (CVD) risk [2-4]. It has been demonstrated in large-scale, randomized, clinical trials that appropriate treatment of hypertriglyceridemia produces a reduction in cardiovascular events (CVEs) [5]. However, clinical trials about therapeutic interventions towards low HDL-C provided fewer convincing results. Anacetrapib reduced CVEs by 9% in the Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) study but it was not clear whether the risk reduction was attributed to the increase in HDL-C [6].

Type 2 diabetes mellitus (T2DM) is also one of the main risk factors of CVD and with lipid profiles that are characterized as high TG accompanied by low HDL-C [7]. Previous studies indicated that individuals with atherogenic dyslipidemia (AD) presented higher risk of CVD in DM patients [8]. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, patients with a combination of high baseline TG ( $\geq 204$  mg/dL, highest tertile and a low baseline HDL-C ( $\leq 34$  mg/dL, lowest tertile) showed possible benefit from fenofibrate plus simvastatin therapy [9]. Standards of medical care in diabetes from American Diabetes Association (ADA) also recommended intensify lifestyle therapy and optimize glycemic control for patients with elevated TG levels and/or low HDL cholesterol [10].

1  
2  
3 Pre-diabetes (Pre-DM) is an abnormal glucose regulation status with high predisposition  
4 to developing T2DM [11]. Pre-DM subjects had similar lipid profile as DM [12]. However, the  
5  
6 prognosis of Pre-DM patients with coronary artery disease (CAD) has less been examined.  
7  
8 Also, whether the Pre-DM alone or accompanied by AD can increase CVD risk in patients with  
9  
10 CAD is lacking. The aim of the study is to test the hypothesis that Pre-DM plus AD had a  
11  
12 significant impact on cardiovascular outcomes in patients with angiography-proven CAD.  
13  
14  
15  
16  
17  
18  
19

## 20 **Materials and Methods**

### 21 *Study Design and Participants*

22  
23 Our study complied with the Declaration of Helsinki and was approved by the hospital's ethical  
24  
25 review board (Fu Wai Hospital & National Center for Cardiovascular Diseases, Beijing, China).  
26  
27 Informed written consents were obtained from all patients enrolled in this study.  
28  
29  
30  
31

32 As described in the flowchart (Fig. 1), from March 2011 to November 2013, 4249  
33  
34 consecutive patients scheduled for coronary angiography because of angina-like chest pain  
35  
36 and/or positive treadmill exercise test or clinically suspected CAD was evaluated for the study.  
37  
38 Among these patients, 382 were excluded because they are not angiography-proven CAD  
39  
40 (coronary stenosis  $\geq 50\%$  of at least one coronary artery). Other patients were excluded for  
41  
42 following reasons: acute coronary syndrome (ACS), previous percutaneous coronary  
43  
44 artery intervention (PCI) and bypass grafting (CABG), heart failure, severe liver and/or renal  
45  
46 insufficiency, thyroid dysfunction, systematic inflammatory disease, malignant disease, and  
47  
48 excessive drinking. Patients were followed up at 6 months' intervals by means of interviewing  
49  
50 directly or using telephone. Trained nurses or physicians who were blinded to the clinical data  
51  
52 fulfilled the interview. The primary endpoints (CVEs) were cardiovascular mortality, non-fatal  
53  
54 myocardial infarction (MI) and stroke. Non-fatal myocardial infarction was diagnosed as  
55  
56  
57  
58  
59  
60

1  
2  
3 positive cardiac troponins along with typical chest pain or typical electrocardiogram serial  
4  
5 changes. Stroke was diagnosed by the presence of typical symptoms and imaging.  
6  
7

8 DM was diagnosed by fasting plasma glucose (FPG)  $\geq 7.0$  mmol/L or the 2-h plasma  
9  
10 glucose of the oral glucose tolerance test  $\geq 11.1$  mmol/L or currently using hypoglycaemic drugs  
11  
12 or insulin. Pre-DM was diagnosed when participants who had no self-reported DM but met the  
13  
14 diagnostic criteria of Pre-DM [13]. Patients who were without DM or Pre-DM were defined as  
15  
16 normal glucose regulation (NGR). Atherogenic dyslipidemia (AD) was defined as  
17  
18 TG  $\geq 1.7$  mmol/L and HDL-C  $< 1.0$  mmol/L for man or  $< 1.3$  mmol/L for women. Hypertension  
19  
20 was defined as a self-reported hypertension, currently taking antihypertensive drugs or  
21  
22 recorded systolic blood pressure (SBP)  $\geq 140$  mmHg and/or diastolic blood pressure (DBP)  $\geq 90$   
23  
24 mmHg for three or more consecutive times. Information of other disease, family history, and  
25  
26 prior therapy of every patient was collected from self-reported medical history.  
27  
28  
29

### 30 31 **Laboratory Analysis** 32

33  
34 Blood samples were obtained from each patient from the cubital vein after at least 12-h fasting.  
35  
36 Concentrations of total cholesterol (TC), TG, LDL-C, HDL-C were measured using automatic  
37  
38 biochemistry analyzer (Hitachi 7150, Tokyo, Japan) in an enzymatic assay. The concentrations  
39  
40 of glucose were measured by enzymatic hexokinase method. HbA1c was measured using  
41  
42 Tosoh Automated Glycohemoglobin Analyser (HLC-723G8, Tokyo, Japan).  
43  
44  
45

### 46 47 **Evaluation of Coronary Severity** 48

49  
50 Angiographic data were evaluated from catheter laboratory records by 3 experienced  
51  
52 interventional cardiologists according to our previous studies [14]. The Gensini score (GS) was  
53  
54 calculated as previously described [15].  
55

### 56 57 **Statistical Analysis** 58

59  
60 The values were expressed as the mean  $\pm$  SD or median (Q1–Q3 quartiles) for the continuous  
variables and the number (percentage) for the categorical variables. The Kolmogorov–Smirnov

1  
2  
3 test was used to test the distribution pattern. The differences of clinical characteristics between  
4  
5 groups were analyzed using the student's t test, analysis of variance, or nonparametric test, chi-  
6  
7 squared statistic test or fisher exact test where appropriate. The event-free survival rates among  
8  
9 groups were estimated by the Kaplan–Meier method and compared by the log-rank test.  
10  
11 Univariate and multivariate Cox regression analyses were performed to calculate the hazard  
12  
13 ratios (HRs). A p-value <0.05 was considered statistically significant. The statistical analyses  
14  
15 were performed with SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA).  
16  
17

### 18 19 ***Patient and Public Involvement***

20  
21 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination  
22  
23 plans of our research  
24  
25  
26  
27  
28  
29

### 30 31 **Results**

32  
33 As presented in Fig. 1, among 3057 subjects, 20.0%, 44.8%, and 35.2.0% were diagnosed as  
34  
35 NGR, Pre-DM, and DM respectively according to ADA criteria. The baseline characteristics  
36  
37 of the study participants were shown in Table 1. The age, body mass index (BMI), glucose,  
38  
39 HbA1c, TG, and high-sensitivity C-reactive protein (hsCRP) were positively associated with  
40  
41 the status of glucose metabolism from NGR to DM (all  $P < 0.001$ ). The proportion of patients  
42  
43 with hypertension was elevated from NGR to DM ( $p < 0.001$ ). Patients with Pre-DM and DM  
44  
45 had higher levels of TC and LDL-C than the NGR group. Meanwhile, DM but not Pre-DM  
46  
47 patients had significantly lower levels of HDL-C and left ventricle ejection fraction (LVEF)  
48  
49 than NGR population. There was no significant difference regarding sex, smoking, drinking,  
50  
51 family history of CAD, creatinine, and medication prescriptions among the three groups  
52  
53  
54  
55  
56  
57  
58  
59  
60  
( $p > 0.05$ ).

1  
2  
3 The coronary severity was compared among different status of glucose metabolism. As  
4 shown in Fig. 2a and 2b, DM group had significantly higher GS ( $p<0.05$ ) while there was no  
5 significant difference between Pre-DM and NGR groups ( $P>0.05$ ). We further divided the  
6 patients into the six groups according to status of glucose metabolism and AD (NGR plus Non-  
7 AD; Pre-DM plus Non-AD; DM plus Non-AD; NGR plus AD; Pre-DM, plus AD; DM plus  
8 AD). We set NGR and Non-AD group as reference and compared its GS with that of other  
9 groups. All the other groups had higher GS than the reference group (all  $p<0.05$ ) except Pre-  
10 DM plus Non-AD and NGR plus AD group ( $p>0.05$  respectively).

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 Over a median follow-up time of 6.1 years (5.1 to 7.5 years), 308 CVEs occurred (112  
23 died, 73 suffered nonfatal MI, 123 had nonfatal strokes). The prevalence of CVEs in NGR,  
24 Pre-DM, and DM group was 7.5%, 9.9%, and 11.8%, respectively. Kaplan–Meier analysis (Fig.  
25 3a) showed that DM subjects had the lowest event-free survival rate among the 3 groups  
26 ( $p<0.05$ ) while there was no significant difference between that of Pre-DM and NGR groups  
27 ( $p>0.05$ ). However, when the patients were evaluated according to both glucose metabolism  
28 and AD status: DM plus Non-AD, Pre-DM plus AD, and DM plus AD groups had significantly  
29 lower cumulative event-free survival rates compared with the reference group (NGR plus Non-  
30 AD group, Fig. 3b, all  $p<0.05$  respectively). As presented in Table 2, univariate Cox regression  
31 models showed that patients with DM had 1.441-fold higher risk of CVEs than NGR subjects  
32 [HR:1.441, 95% coincidence interval (CI):1.018-2.041,  $p<0.05$ ]. Additional adjustment for  
33 other variables did not change the significance of association. The presence of Pre-DM did not  
34 show increase in CVEs risk when compared with NGR group ( $p>0.05$ ). Moreover, multivariate  
35 Cox regression analyses according to both glucose metabolism and AD status indicated that  
36 patients in DM plus non-AD, Pre-DM plus AD, and DM plus AD groups had 1.62-fold (95%CI:  
37 1.01-2.46), 1.73-fold (95%CI:1.08-2.76), and 1.81-fold (95%CI:1.13-2.91) higher risk of CVEs  
38 (Table 3, all  $p<0.05$  respectively).

## Discussion

The causality of high TG and/or low HDL-C to ASCVD has been controversial during the past decades. Previous prospective studies have shown that patients with high TG combined with low HDL-C may be more likely to develop ASCVD, especially in those with DM [16]. In this study, we investigated the impact of AD on cardiovascular outcomes in stable, angiography-proven CAD patients in different glucose metabolism status. We found that patients with DM but not those with Pre-DM had more severe coronary stenosis and higher risk of CVEs when the patients were simply divided into the three groups: DM, Pre-DM, and NGR. Interestingly, when patients were categorized according to both status of glucose metabolism and AD, patient with Pre-DM plus AD had higher GS and 1615-fold increased risk of CVEs compared with that in subjects with NGR and Non-AD. Thus, our study, for the first time, suggested that the presence of Pre-DM had significant impact on cardiovascular outcomes when combined with AD.

High TG and low HDL-C are common lipid abnormalities among adult population, especially in Chinese subjects. According to DYSlipidemia International Study (DYSIS), 41.8% patients had high TG and 31.9% patients had low HDL-C among the Chinese population in primary prevention [17]. Additionally, studies about lowering TG and raising HDL-C on reducing CVD risk were with inconsistent results [6,9]. For example, fibrates did not associate with conclusive effect in ASCVD reduction in ACCORD trials while patients who received 2 g of icosapent ethyl twice daily had lower risk of ischemic events in Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) [9,18]. However, in randomized controlled trials (RCTs), cholesteryl ester transfer protein (CETP) inhibitors, which aimed at increasing plasma HDL-C, failed to reduce CVEs rates [9, 19-21]. In the meanwhile, Mendelian analysis involving about 20,000 MI individuals and 50,000 controls demonstrated that 1 SD increase in TG levels was associated with 54% increase risk

1  
2  
3 of MI [22]. In contrast, no such association was found for patients with low baseline levels of  
4 HDL-C [3]. Moreover, high TG and low HDL-C were often regarded as a whole and defined  
5 as AD or metabolic dyslipidemia in many studies. In the EPIC-Norfolk prospective population  
6 study, healthy men with AD had 61% higher risk of CAD than those with normal TG and HDL  
7 [23]. Of noted, patients with obesity, insulin resistance or other metabolic abnormalities had  
8 higher prevalence of high TG and/or low HDL-C [24].  
9

10  
11  
12  
13  
14  
15  
16  
17 DM was the most common metabolic disease in the 21<sup>st</sup> century and approximately 415  
18 million adults were with T2DM worldwide [25]. Prevalence of total diagnosed and  
19 undiagnosed diabetes in China also reached 10.9% in 2013 [26]. What's more, CAD was a  
20 common comorbidity and increased mortality in patients with DM. According to previous  
21 studies, DM patients without angiography-proven CAD showed low risk of MI or CVEs  
22 (defined as death, cardiac death, and MI), but the DM and CAD combination further increased  
23 the risk of ischemic stroke [27-28]. In our previous studies, among patients with established  
24 CAD, individuals with DM were associated with significantly higher risk of worse prognosis  
25 when they were combined with other CAD risk factors, including hypertension and Lp(a)-  
26 hyperlipoproteinemia [14, 29]. Therefore, in the present study, among patients with stable CAD,  
27 identifying whether AD is a risk factor for worse prognosis might be crucial.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42  
43 In strong heart study, high TG plus low HDL levels were associated with a 1.54-fold  
44 greater occurrence risk for CAD and a 2.13-fold occurrence risk for stroke in community based  
45 African Americans with DM [8]. In a large cohort of 28,318 DM subjects, increased CAD risk  
46 was observed in both men and women with AD [16]. In the ACCORD trial, for participants  
47 with DM, fenofibrate plus simvastatin 40mg exhibited a 31% reduction in CVEs in the  
48 subgroup with baseline high TG and low HDL-C [9]. Other studies, such as Pemafibrate to  
49 Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (PROMINENT) study, also provided evidence about the risk of high TG and/or low HDL-C in  
4  
5 DM patients [30].  
6  
7

8 In fact, more attention has recently been paid to the prevention of DM and the clinical  
9  
10 characters in the early phase of impaired glucose metabolism. Pre-DM was an intermediate  
11  
12 state between NGR and DM and with high predisposition to develop DM. This metabolic  
13  
14 condition was often reversible. The rate of individuals with Pre-DM was almost three times  
15  
16 higher than DM worldwide and in China (35.7% vs.10.9% in China) [25,31]. The prevalence  
17  
18 of Pre-DM and CVEs risk have long been debating. Despite the differences of cut-off point in  
19  
20 diagnose of pre-DM, studies and meta-analysis using blood glucose and HbA1c according to  
21  
22 2003 ADA guideline also had different results [32-33]. In our study population, as previously  
23  
24 reported, the predictive value of Pre-DM for CVEs was less significant, which was also  
25  
26 consistent with studies conducted by Liu et al and Qiu et al [19]. In the present study, 21.8%,  
27  
28 26.6% and 31.2% of patients had AD in NGR, Pre-DM and DM groups. Both Pre-DM and DM  
29  
30 groups had higher rate of AD than NGR group. As the main findings of our study, stable CAD  
31  
32 patients with Pre-DM plus AD had higher GS and increased risk of CVEs while no statistically  
33  
34 significant difference were observed between Pre-DM alone and NGR plus Non-AD groups.  
35  
36 Therefore, similar attention should be given to patients with Pre-DM and DM when they were  
37  
38 with AD.  
39  
40  
41  
42  
43  
44

45 The present study had several virtues compared with previous published reports. Very few  
46  
47 studies have evaluated the differences of coronary severity and outcomes according to both  
48  
49 status of glucose metabolism and AD, especially in those with stable CAD. In addition,  
50  
51 previous studies were also limited by the fact that the risk of high TG and/ or low HDL-C levels  
52  
53 were analyzed separately within DM or NGR population, neglecting of the potential high risk  
54  
55 which was caused by the interaction of lipid and glucose. Moreover, there were no such studies  
56  
57 about the impacts of AD on cardiovascular outcomes in CAD patients with Pre-DM.  
58  
59  
60



1  
2  
3 Apparently, a large sample size of angiography-proven CAD patients with high prevalence of  
4 DM and pre-DM were enrolled in the present study. Hard endpoints containing nonfatal strokes,  
5 nonfatal MI, and cardiovascular mortality were also observed during a relatively long follow-  
6 up period. Thereby, our study provided important information regarding dyslipidemia, pre-DM  
7 and outcome, which may influence our treatment decision for CAD patients with pre-DM.  
8  
9

10  
11  
12  
13  
14  
15 Nevertheless, there are still several limitations in the present study. Firstly, this is a single  
16 center study among Chinese patients with stable CAD. Secondly, we measured triglyceride and  
17 HDL-C only at the baseline, the follow-up levels of TG/HDL-C may also be clinically  
18 significant. Thirdly, we did not assess the all metabolic factors and parameters about insulin  
19 resistance due to the features of patients in our study.  
20  
21  
22  
23  
24  
25

26  
27 In conclusion, in our large sample size with long-term follow-up study, data, for the first  
28 time, indicated that the Pre-DM patients with AD had a significant impact on CVDs suggesting  
29 that the AD control in Pre-DM may also be a target for improving clinical outcomes.  
30  
31  
32  
33  
34  
35

### 36 **Contributors**

37  
38 YG and J-LJ analyzed the data and drafted the manuscript. J-JL planned and designed the  
39 study. The rest of the authors were involved in collecting and researching data, reviewing and  
40 editing manuscript. All authors read and approved the final manuscript.  
41  
42  
43  
44  
45  
46  
47

### 48 **Funding**

49  
50  
51 This work was partially supported by the Capital Health Development Fund (201614035),  
52 CAMS Major Collaborative Innovation Project (2016-I2M-1-011), Fundamental Research  
53 Funds for the Central Universities(2018-F05), and Youth Research Fund of Peking Union  
54 Medical College(2018-XHQ03).  
55  
56  
57  
58  
59  
60

## Competing interests

None declared

## Patient consent

Obtained.

## Ethics approval

The study was performed according to the Declaration of Helsinki, and the hospital ethics review board (Fuwai Hospital and National Center for Cardiovascular Diseases, Beijing, China) approved the protocol.

## Data sharing statement

The technical appendix, statistical code and data set are available from the corresponding author.

## References

- [1] Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388:2532–2561.
- [2] Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation* 2007;115:450–458.
- [3] Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. *Nat Rev Genet* 2017;18:331–344.

- 1  
2  
3 [4] Alexander DD, Miller PE, Van Elswyk ME, et al. A Meta-analysis of randomized controlled trials and  
4 prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and  
5 coronary heart disease risk. *Mayo Clin Proc* 2017;92:15–29.  
6  
7  
8  
9 [5] Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein  
10 cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol* 2008;51:724–  
11 730.  
12  
13  
14 [6] HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of anacetrapib in  
15 patients with atherosclerotic vascular disease. *N Engl J Med* 2017;377:1217–27.  
16  
17  
18 [7] Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with  
19 type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association  
20 and the American Diabetes Association. *Circulation*. 2015;132:691–718.  
21  
22  
23 [8] Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart  
24 Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. *Diabetes Care*.  
25 2017;40:529–537.  
26  
27  
28 [9] Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy  
29 in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563–1574.  
30  
31  
32 [10] American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes—2018.  
33 *Diabetes Care* 2018;41(Suppl. 1): S55–S64.  
34  
35  
36 [11] Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes  
37 development. *Lancet*. 2012;379:2279–90.  
38  
39  
40 [12] Nam GE, Han K, Kim DH, et al. Relationship between dyslipidemia and albuminuria in prediabetic  
41 adults: the Korea National Health and Nutrition Examination Survey 2011–2012. *Endocrine*. 2015;48:557–  
42 565.  
43  
44  
45 [13] American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes care*.  
46 2011;34(suppl 1):S62–S69.  
47  
48  
49 [14] Liu HH, Cao YX, Li S, et al. Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the  
50 Coronary Severity and Cardiovascular Outcomes. *Hypertension*. 2018;71:1039–1046  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [15] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease.  
4  
5 Am J Cardiol. 1983;51:606.  
6  
7 [16] Rana JS, Liu JY, Moffet HH, et al. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in  
8  
9 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. Am J Cardiol.  
10  
11 2015;116:1700-1704.  
12  
13 [17] Zhao S, Wang Y, Mu Y, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents  
14  
15 in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235:463-469.  
16  
17 [18] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for  
18  
19 Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.  
20  
21 [19] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary  
22  
23 events. N Engl J Med. 2007;357(21):2109-2122.  
24  
25 [20] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary  
26  
27 syndrome. N Engl J Med. 2012;367(22):2089-2099.  
28  
29 [21] Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med.  
30  
31 2017;376(20):1933-1942.  
32  
33 [22] Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ  
34  
35 Res 2016;118:579-585.  
36  
37 [23] Rana JS, Visser ME, Arsenault B, et al. Metabolic dyslipidemia and risk of future coronary heart disease  
38  
39 in apparently healthy men and women: the EPIC-Norfolk prospective population study. Int J Cardiol. 2010  
40  
41 Sep 3;143:399-404.  
42  
43 [24] Adiels M, Olofsson SO, Taskinen MR, Bor'en J. Overproduction of very low-density lipoproteins is  
44  
45 the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-  
46  
47 1236.  
48  
49 [25] Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for  
50  
51 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271-281.  
52  
53 [26] Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in  
54  
55 2013. JAMA. 2017;317(24):2515-2523.  
56  
57  
58  
59  
60

1  
2  
3 [27] Olesen KKW, Madsen M, Gyldenkerne C, et al. Diabetes Mellitus Is Associated With Increased Risk  
4 of Ischemic Stroke in Patients With and Without Coronary Artery Disease. *Stroke*. 2019;50(12):3347-3354.  
5

6  
7 [28] Olesen KKW, Madsen M, Egholm G, et al. Patients With Diabetes Without Significant Angiographic  
8 Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a  
9 Real-World Population Receiving Appropriate Prophylactic Treatment. *Diabetes Care*. 2017;40(8):1103-  
10 1110.  
11

12  
13  
14  
15 [39] Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and Cardiovascular Outcomes in Patients With  
16 Coronary Artery Disease and Prediabetes or Diabetes. *Diabetes Care*. 2019;42(7):1312-1318.  
17

18  
19 [30] Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the Pemafibrate to Reduce  
20 Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. *Am*  
21 *Heart J*. 2018;206:80-93  
22

23  
24 [31] Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the  
25 United States, 1988-2012. *JAMA* 2015;314: 1021–1029.  
26

27  
28 [32] Laukkanen JA, Mäkikallio TH, Ronkainen K, et al. Impaired fasting plasma glucose and type 2 diabetes  
29 are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. *Diabetes Care*  
30 2013;36:1166-1171.  
31

32  
33 [33] Rijkkelijkhuizen JM, Nijpels G, Heine RJ, et al. High risk of cardiovascular mortality in individuals with  
34 impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. *Diabetes Care*  
35 2007;30:332-336.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Legends

**Figure 1** Flowchart of the study

**Figure 2** Coronary severity in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia \* for  $p < 0.05$

**Figure 3** Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia

## Tables

**Table 1. Baseline characteristics of the participants according to different glucose metabolism**

	<b>Total n=3057</b>	<b>NGR n=610</b>	<b>Pre-DM n=1370</b>	<b>DM n=1077</b>	<b>P</b>
<b>Clinical factors</b>					
Age, years	58.5±9.8	55.5±10.0	58.8±9.4	59.9±9.8	<0.001
Male, n (%)	2149(70.3)	438(71.8)	956(69.8)	755(70.1)	0.651
BMI (kg/m <sup>2</sup> )	25.6±3.2	25.0±3.0	25.5±3.2	26.1±3.2	<0.001
HT, n (%)	1904(62.3)	339(55.6)	804(58.7)	761(70.7)	<0.001
Family history of CAD	494(16.2)	112(18.4)	221(16.1)	161(14.9)	0.188
Current Smoker, n (%)	1580(51.7)	307(50.3)	714(52.1)	559(51.7)	0.751
Drinking, n (%)	764(25.0)	171(28.0)	333(24.3)	260(24.1)	0.152
<b>Laboratory factors</b>					
Glucose (mmol/L)	5.6±1.6	4.7±0.4	5.1±0.6	6.7±2.1	<0.001
HbA1c (%)	6.3±1.1	5.4±0.2	6.0±0.2	7.3±1.2	<0.001
Creatinine (µmol/L)	73.6±14.1	73.5±14.1	73.3±13.1	74.1±15.2	0.335
hsCRP (µmol/L)	1.5(0.8-2.9)	1.1(0.6-2.2)	1.5(0.8-2.9)	1.7(0.9-3.3)	<0.001
TC (mmol/L)	4.13±1.02	4.00±1.00	4.18±1.00	4.13±1.05	0.001
HDL-C (mmol/L)	1.07±0.28	1.10±0.30	1.09±0.27	1.05±0.27	<0.001
LDL-C (mmol/L)	2.46±0.88	2.37±0.86	2.51±0.87	2.46±0.89	0.003
TG (mmol/L)	1.48(1.09-2.03)	1.38(1.00-1.85)	1.44(1.09-1.98)	1.59(1.17-2.18)	<0.001
LVEF (%)	63.3±7.9	64.0±6.9	63.2±8.4	63.0±7.8	0.026
GS	26(9-44)	24(8-34)	24(8-40)	32(12-56)	<0.001
<b>Prior Medications</b>					
Aspirin, n (%)	2657(86.9)	519(85.1)	1203(87.8)	935(86.8)	0.249
Statins, n (%)	2193(71.7)	423(69.3)	978(71.4)	792(73.5)	0.171
ACEIs/ARBs, n (%)	798(26.1)	149(24.4)	364(26.6)	285(26.5)	0.572
β-blockers, n (%)	1598()	294(48.2)	721(52.6)	573(53.6)	0.112

Data were expressed as mean ± SD, median with 25th and 75th percentile or n (%).

BMI: body mass index; HT: hypertension; CAD: coronary artery disease; HbA1c: haemoglobin A1c; hsCRP: high sensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; GS: gensini score; ACEIs: angiotensin-converting enzymes; ARBs: angiotensin receptor blocker

**Table 2. Cox regression models in predicting cardiovascular events according to different glucose metabolism**

Diabetic status (n, events/subjects)	HR (95%CI)		
	Unadjusted model	model 1	model 2
<b>NGR (46/610)</b>	Ref	Ref	Ref
<b>Pre-DM (135/1379)</b>	1.31 (0.94-1.83)	1.29 (0.92-1.81)	1.25 (0.89-1.76)
<b>DM (127/1077)</b>	*1.56 (1.11-2.19)	*1.53 (1.09-2.15)	*1.44 (1.02-2.04)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus;

Model 1 adjusted for age and sex; model 2 adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease, Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride and high sensitive C-reactive protein;



**Table 3. Cox Regression Models in Predicting cardiovascular events according to different status of glucose metabolism and atherogenic dyslipidemia**

DM/AD category	Events/Subjects 308/3057	HR (95%CI)	
		Crude Model	Adjusted Model
<b>NGR, Non-AD</b>	31/477	Ref	Ref
<b>Pre-DM, Non-AD</b>	92/1005	1.42 (0.94-2.13)	1.35 (0.90-2.04)
<b>DM, Non-AD</b>	84/741	*1.75 (1.16-2.64)	*1.62 (1.06-2.46)
<b>NGR, AD</b>	15/133	1.74 (0.94-3.22)	1.74 (0.94-3.24)
<b>Pre-DM, AD</b>	43/365	*1.81 (1.14-2.88)	*1.73 (1.08-2.76)
<b>DM, AD</b>	43/336	*1.95(1.23-3.09)	*1.81 (1.13-2.91)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; AD: atherogenic dyslipidemia;

Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease, Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, and high sensitive C-reactive protein;

## Figure legends

**Figure 1** Flowchart of the study. CAD, coronary artery disease; ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; NGR: normal glucose regulation; Pre-DM, pre-diabetes mellitus; DM, diabetes mellitus.

**Figure 2** Coronary severity in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia

\* for  $p < 0.05$ ; \*\* for  $p < 0.01$

**Figure 3** Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia




Figure 1 Flowchart of the study.

188x179mm (300 x 300 DPI)




Figure 2 Coronary severity in participants according to a. different glucose metabolism; b. different status of glucose metabolism and atherogenic dyslipidemia \* for  $p < 0.05$ ; \*\* for  $p < 0.01$

174x269mm (300 x 300 DPI)




Figure 3 Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to a. different glucose metabolism; b. different status of glucose metabolism and atherogenic dyslipidemia

183x250mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7 7 7 7
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	7 6-7
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6-7 6-7 6-7
Outcome data	15*	Report numbers of outcome events or summary measures over time	7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
2			(b) Report category boundaries when continuous variables were categorized	6-7
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7-8
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9
10				
11	<b>Discussion</b>			
12				
13	Key results	18	Summarise key results with reference to study objectives	9
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
15				
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	10-11
20				
21	<b>Other information</b>			
22				
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
24				
25				

26 \*Give information separately for exposed and unexposed groups.

27  
28  
29 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Prognostic importance of atherogenic dyslipidemia in patients with stable coronary artery disease and pre-diabetes: a prospective, large Chinese cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037340.R1
Article Type:	Original research
Date Submitted by the Author:	21-Jul-2020
Complete List of Authors:	<p>Jin, Jing-Lu; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Cao, Ye-Xuan; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Wu, Li-Guo; TangXian Peoples Hospital, Hebei Province</p> <p>You, Xiang-Dong; TangXian Peoples Hospital, Hebei Province</p> <p>Guo, Na; TangXian Peoples Hospital, Hebei Province</p> <p>Guo, Yuan-Lin; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Wu, Na-Qiong; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Zhu, Cheng-Gang ; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Xu, Rui-Xia; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Liu, Hui-Hui; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia</p> <p>Sun, Jing; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Dong, Qian; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Gao, Ying; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Li, Jian-Jun; Chinese Academy of Medical Science, Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p>



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Primary Subject Heading</b> :	Epidemiology
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Lipid disorders < DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, Coronary heart disease < CARDIOLOGY



BMJ Open: first published as 10.1136/bmjopen-2020-037340 on 17 January 2021. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**BMJ Open(bmjopen-2020-037340R1)**

**2020-07-20**

**Title:** Prognostic importance of atherogenic dyslipidemia in patients with stable coronary artery disease and pre-diabetes: a prospective, large Chinese cohort study

**Running Title:** lipid, glucose and outcomes

**Authors:** Jing-Lu Jin<sup>1</sup>, MD; Ye-Xuan Cao<sup>1</sup>, MD; Li-Guo Wu<sup>2</sup>, MD; Xiang-Dong You<sup>2</sup>, MD; Na Guo<sup>2</sup>, MD; Yuan-Lin Guo<sup>1</sup>, MD; Na-Qiong Wu<sup>1</sup>; MD, Cheng-Gang Zhu<sup>1</sup>; MD, Rui-Xia Xu, PhD; Hui-Hui Liu,<sup>1</sup> MD; Jing Sun<sup>1</sup>, MS; Qian Dong<sup>1</sup>, MS; Ying Gao<sup>1\*</sup>, MD; Jian-Jun Li<sup>1\*</sup>, MD, PhD

**Address:** 1. State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China. 2. TangXian Peoples Hospital, Hebei Province, 072350, China.

**\*Correspondence:** Professor Jian-Jun Li, MD, PhD. **Tel:** 86+10+88396077; **Fax:** 86+10+88396584; **E-mail:** lijianjun938@126.com or Professor Ying Gao, MD. **E-mail:** cmuxyg@sina.com; BeiLiShi Road 167, Beijing 100037, China.

**ORCID:** 0000-0003-2536-4364

## Abstract

**Objective:** The aim of the study is to investigate the impacts of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) dyslipidemia on prognosis in coronary artery disease patients with different glucose metabolism status.

**Design:** An observational cohort study

**Setting/Participants:** A total of 3057 patients with stable coronary artery disease (CAD) were consecutively enrolled and divided into 3 groups according to different glucose metabolism status. Atherogenic dyslipidemia (AD) was defined as  $TG \geq 1.7 \text{ mmol/L}$  and  $HDL-C < 1.0 \text{ mmol/L}$  for man or  $< 1.3 \text{ mmol/L}$  for women. These patients were further classified into 6 subgroups by status of atherogenic dyslipidemia. All subjects were followed up for the cardiovascular events (CVEs).

**Primary outcome measure:** The primary endpoints (CVEs) were cardiovascular mortality, non-fatal myocardial infarction and stroke.

**Results:** During a median follow-up of 6.1 years, 308 (10.1%) CVEs occurred. No significant difference in occurrence of CVEs was observed between NGR and Pre-DM groups [Hazard Ratio (HR): 1.25, 95% confidence interval (CI): 0.89-1.76] while DM group presented 1.45-fold higher risk of CVEs (HR:1.45, 95%CI: 1.02-2.05). When the participants were categorized according to combined status of two parameters, the cardiovascular risk was significantly elevated in Pre-DM or DM plus AD group compared with the NGR plus Non-AD group (HR: 1.76, 95%CI: 1.10-2.80 and HR: 1.87, 95%CI: 1.17-2.98).

**Conclusions:** The present study indicated that the presence of atherogenic dyslipidemia have a significant impact on CVEs in Pre-DM.

**Keywords:** triglyceride, HDL-C, pre-diabetes, prognosis

### Strengths and limitations of this study

- Fill the gap of knowledge on the predictive value of atherogenic dyslipidemia in patients with impaired glucose metabolism.
- Using hard endpoints during a relatively long follow-up period.
- Giving evidence on treatment strategies of patients with diabetes and coronary artery disease.
- For inevitable reasons, restricted to the predictive value of baseline parameters.
- Studies in different populations are in need.

## Introduction

Dyslipidemia is one of the key drivers in atherogenesis. Lipid lowering therapy targeting at low density lipoprotein cholesterol (LDL-C) has been proved to be efficient in decreasing the progression of arteriosclerotic cardiovascular disease (ASCVD) [1]. Moreover, strong evidence in epidemiological, genetic and prospective cohort studies verifies that high triglyceride (TG) and/or low levels of high density lipoprotein cholesterol (HDL-C) are associated with cardiovascular disease (CVD) risk [2-4]. It has been demonstrated in large-scale clinical trials that hypertriglyceridemia was associated with increased cardiovascular events (CVEs) [5]. However, clinical trials about therapeutic interventions towards low HDL-C provided fewer convincing results. Anacetrapib reduced CVEs by 9% in the Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) study but it was not clear whether the risk reduction was attributed to the increase in HDL-C [6].

Type 2 diabetes mellitus (T2DM) is also one of the main risk factors of CVD and with lipid profiles that are characterized as high TG accompanied by low HDL-C [7]. Previous studies indicated that individuals with atherogenic dyslipidemia (AD) presented higher risk of CVD in DM patients [8]. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, patients with a combination of high baseline TG ( $\geq 204$  mg/dL, highest tertile and a low baseline HDL-C ( $\leq 34$  mg/dL, lowest tertile) showed possible benefit from fenofibrate plus simvastatin therapy compared to simvastatin alone [9]. Standards of medical care in diabetes from American Diabetes Association (ADA) also recommended intensify lifestyle therapy and optimize glycemic control for patients with elevated TG levels and/or low HDL cholesterol [10].

Pre-diabetes (Pre-DM) is an abnormal glucose regulation status with high predisposition to developing T2DM [11]. Pre-DM subjects had similar lipid profile as DM [12]. However, the prognosis of Pre-DM patients with coronary artery disease (CAD) has less been examined.

1  
2  
3 Also, whether the Pre-DM alone or accompanied by AD can increase CVD risk in patients with  
4 CAD is lacking. The aim of the study is to test the hypothesis that Pre-DM plus AD had a  
5 significant impact on cardiovascular outcomes in patients with angiography-proven CAD.  
6  
7  
8  
9  
10

## 11 12 **Materials and Methods**

### 13 *Study Design and Participants*

14  
15  
16 Our study complied with the Declaration of Helsinki and was approved by the hospital's ethical  
17 review board (Fu Wai Hospital & National Center for Cardiovascular Diseases, Beijing, China).  
18  
19 Informed written consents were obtained from all patients enrolled in this study.  
20  
21  
22  
23  
24

25 As described in the flowchart (Fig. 1), from March 2011 to November 2013, 4249  
26 consecutive patients scheduled for coronary angiography because of angina-like chest pain  
27 and/or positive treadmill exercise test or clinically suspected CAD was evaluated for the study.  
28  
29 Among these patients, 413 were excluded because they are not angiography-proven CAD  
30 (coronary stenosis  $\geq 50\%$  of at least one coronary artery). Other patients were excluded for  
31 following reasons: 527 had acute coronary syndrome (ACS), previous percutaneous coronary  
32 coronary artery intervention (PCI) and bypass grafting (CABG) or heart failure; 231 patients  
33 were with severe liver and/or renal insufficiency, thyroid dysfunction, systematic inflammatory  
34 disease, malignant disease, or indulge in excessive drinking. 21 patients lost follow-up. Patients  
35 were followed up at 6 months' intervals by means of interviewing directly or using telephone.  
36  
37 Trained nurses or physicians who were blinded to the clinical data fulfilled the interview. The  
38 primary endpoints (CVEs) were cardiovascular mortality, non-fatal myocardial infarction (MI)  
39 and stroke. Non-fatal myocardial infarction was diagnosed as positive cardiac troponins along  
40 with typical chest pain or typical electrocardiogram serial changes. Stroke was diagnosed by  
41 the presence of typical symptoms and imaging. Cardiovascular mortality was defined as death  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 mainly caused by MI, congestive heart failure, stroke, malignant arrhythmia and other  
4 structural or functional cardiac diseases.  
5  
6

7  
8 DM was diagnosed by fasting plasma glucose (FPG)  $\geq 7.0$  mmol/L or the 2-h plasma  
9 glucose of the oral glucose tolerance test  $\geq 11.1$  mmol/L or currently using hypoglycaemic drugs  
10 or insulin. Pre-DM was diagnosed when participants who had no self-reported DM but met the  
11 diagnostic criteria of Pre-DM [13]. Patients who were without DM or Pre-DM were defined as  
12 normal glucose regulation (NGR). Atherogenic dyslipidemia (AD) was defined as  
13 TG  $\geq 1.7$  mmol/L and HDL-C  $< 1.0$  mmol/L for man or  $< 1.3$  mmol/L for women. Hypertension  
14 was defined as a self-reported hypertension, currently taking antihypertensive drugs or  
15 recorded systolic blood pressure (SBP)  $\geq 140$  mmHg and/or diastolic blood pressure (DBP)  $\geq 90$   
16 mmHg for three or more consecutive times. Information of other disease, family history, and  
17 prior therapy of every patient was collected from self-reported medical history.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 31 ***Laboratory Analysis*** 32

33  
34 Blood samples were obtained from each patient from the cubital vein after at least 12-h fasting.  
35 Concentrations of total cholesterol (TC), TG, LDL-C, HDL-C were measured using automatic  
36 biochemistry analyzer (Hitachi 7150, Tokyo, Japan) in an enzymatic assay. The concentrations  
37 of glucose were measured by enzymatic hexokinase method. HbA1c was measured using  
38 Tosoh Automated Glycohemoglobin Analyser (HLC-723G8, Tokyo, Japan).  
39  
40  
41  
42  
43  
44

### 45 46 ***Evaluation of Coronary Severity*** 47

48  
49 Angiographic data were evaluated from catheter laboratory records by 3 experienced  
50 interventional cardiologists according to our previous studies [14]. The Gensini score (GS) was  
51 calculated as previously described [15].  
52  
53  
54

### 55 56 ***Statistical Analysis*** 57

58  
59 The values were expressed as the mean  $\pm$  SD or median (Q1–Q3 quartiles) for the continuous  
60 variables and the number (percentage) for the categorical variables. The Kolmogorov–Smirnov



1  
2  
3 test was used to test the distribution pattern. The differences of clinical characteristics between  
4  
5 groups were analyzed using the student's t test, analysis of variance, or nonparametric test, chi-  
6  
7 squared statistic test or fisher exact test where appropriate. The event-free survival rates among  
8  
9 groups were estimated by the Kaplan–Meier method and compared by the log-rank test.  
10  
11 Univariate and multivariate Cox regression analyses were performed to calculate the hazard  
12  
13 ratios (HRs). Adjust variables were traditional cardiovascular risk factors including age, sex,  
14  
15 body mass index (BMI), smoking, hypertension, family history of CAD, GS, left ventricular  
16  
17 ejection fraction (LVEF), LDL-C, HDL-C, TG, high sensitive C-reactive protein and baseline  
18  
19 statins. A p-value <0.05 was considered statistically significant. The statistical analyses were  
20  
21 performed with SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA).  
22  
23  
24  
25

### 26 ***Patient and Public Involvement***

27  
28 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination  
29  
30 plans of our research.  
31  
32  
33  
34  
35  
36

### 37 **Results**

38  
39 As presented in Fig. 1, among 3057 subjects, 20.0%, 44.8%, and 35.2.0% were diagnosed as  
40  
41 NGR, Pre-DM, and DM respectively according to ADA criteria. The baseline characteristics  
42  
43 of the study participants were shown in Table 1. The age, BMI, glucose, HbA1c, TG, and high-  
44  
45 sensitivity C-reactive protein (hsCRP) were positively associated with the status of glucose  
46  
47 metabolism from NGR to DM (all  $P < 0.001$ ). The proportion of patients with hypertension was  
48  
49 elevated from NGR to DM ( $p < 0.001$ ). Patients with Pre-DM and DM had higher levels of TC  
50  
51 and LDL-C than the NGR group. Meanwhile, DM but not Pre-DM patients had significantly  
52  
53 lower levels of HDL-C and LVEF than NGR population. There was no significant difference  
54  
55 regarding sex, smoking, drinking, family history of CAD, creatinine, and medication  
56  
57 prescriptions among the three groups ( $p > 0.05$ ).  
58  
59  
60

1  
2  
3 The coronary severity was compared among different status of glucose metabolism. As  
4 shown in Fig. 2a and 2b, DM group had significantly higher GS ( $p<0.05$ ) while there was no  
5 significant difference between Pre-DM and NGR groups ( $P>0.05$ ). We further divided the  
6 patients into the six groups according to status of glucose metabolism and AD (NGR plus Non-  
7 AD; Pre-DM plus Non-AD; DM plus Non-AD; NGR plus AD; Pre-DM plus AD; DM plus  
8 AD). We set NGR and Non-AD group as reference and compared its GS with that of other  
9 groups. All the other groups had higher GS than the reference group (all  $p<0.05$ ) except Pre-  
10 DM plus Non-AD and NGR plus AD group ( $p>0.05$  respectively). As shown in Supplemental  
11 Table S1, multivariate regression logistic regression analysis revealed that DM group was  
12 independently associated with high GS (median as cut-off,  $p<0.05$ ). Pre-DM plus AD group  
13 and DM plus AD group were also independently associated with presence of high GS(all  
14  $p<0.05$ , Supplemental Table S2).

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31 Over a median follow-up time of 6.1 years (5.1 to 7.5 years), 308 CVEs occurred (112  
32 died, 73 suffered nonfatal MI, 123 had nonfatal strokes). The prevalence of CVEs in NGR,  
33 Pre-DM, and DM group was 7.5%, 9.9%, and 11.8%, respectively. Kaplan–Meier analysis (Fig.  
34 3a) showed that DM subjects had the lowest event-free survival rate among the 3 groups  
35 ( $p<0.05$ ) while there was no significant difference between that of Pre-DM and NGR groups  
36 ( $p>0.05$ ). However, when the patients were evaluated according to both glucose metabolism  
37 and AD status: DM plus Non-AD, Pre-DM plus AD, and DM plus AD groups had significantly  
38 lower cumulative event-free survival rates compared with the reference group (NGR plus Non-  
39 AD group, Fig. 3b, all  $p<0.05$  respectively). As presented in Table 2, univariate Cox regression  
40 models showed that patients with DM had 1.45-fold higher risk of CVEs than NGR subjects  
41 [HR:1.45, 95% coincidence interval (CI):1.02-2.05,  $p<0.05$ ]. The Gensini score was also  
42 associated with CVEs [HR:1.004, 95% CI:1.001-1.008,  $p<0.05$ ]. Additional adjustment for  
43 confounding variables including Gensini score did not change the significance of association.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The presence of Pre-DM did not show increase in CVEs risk when compared with NGR group  
4 (p>0.05). Moreover, multivariate Cox regression analyses according to both glucose  
5 metabolism and AD status indicated that patients in DM plus non-AD, Pre-DM plus AD, and  
6 DM plus AD groups had 1.68-fold (95%CI:1.11-2.56), 1.76-fold (95%CI: 1.10-2.80), and 1.87-  
7 fold (95%CI: 1.17-2.98) higher risk of CVEs (Table 3, all p<0.05 respectively).  
8  
9  
10  
11  
12  
13  
14  
15  
16

## 17 **Discussion**

18  
19  
20 The causality of high TG and/or low HDL-C to ASCVD has been controversial during the past  
21 decades. Previous prospective studies have shown that patients with high TG combined with  
22 low HDL-C may be more likely to develop ASCVD, especially in those with DM [16]. In this  
23 study, we investigated the impact of AD on cardiovascular outcomes in stable, angiography-  
24 proven CAD patients in different glucose metabolism status. We found that patients with DM  
25 but not those with Pre-DM had more severe coronary stenosis and higher risk of CVEs when  
26 the patients were simply divided into the three groups: DM, Pre-DM, and NGR. Interestingly,  
27 when patients were categorized according to both status of glucose metabolism and AD, patient  
28 with Pre-DM plus AD had higher GS and 1.76-fold increased risk of CVEs compared with that  
29 in subjects with NGR and Non-AD. Thus, our study, for the first time, suggested that the  
30 presence of Pre-DM had significant impact on cardiovascular outcomes when combined with  
31 AD.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 High TG and low HDL-C are common lipid abnormalities among adult population,  
49 especially in Chinese subjects. According to DYSlipidemia International Study (DYSIS), 41.8%  
50 patients had high TG and 31.9% patients had low HDL-C among the Chinese population in  
51 primary prevention [17]. Additionally, studies about lowering TG and raising HDL-C on  
52 reducing CVD risk were with inconsistent results [6,9]. For example, fibrates did not associate  
53 with conclusive effect in ASCVD reduction in ACCORD trials while patients who received 2  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 g of icosapent ethyl twice daily had lower risk of ischemic events in Reduction of  
4 Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) [9,18].  
5  
6 However, in randomized controlled trials (RCTs), cholesteryl ester transfer protein (CETP)  
7  
8 inhibitors, which aimed at increasing plasma HDL-C, failed to reduce CVEs rates [9, 19-21].  
9  
10 In the meanwhile, Mendelian analysis involving about 20,000 MI individuals and 50,000  
11  
12 controls demonstrated that 1 SD increase in TG levels was associated with 54% increase risk  
13  
14 of MI [22]. In contrast, no such association was found for patients with low baseline levels of  
15  
16 HDL-C [3]. Moreover, high TG and low HDL-C were often regarded as a whole and defined  
17  
18 as AD or metabolic dyslipidemia in many studies. In the EPIC-Norfolk prospective population  
19  
20 study, healthy men with AD had 61% higher risk of CAD than those with normal TG and HDL  
21  
22 [23]. Of noted, patients with obesity, insulin resistance or other metabolic abnormalities had  
23  
24 higher prevalence of high TG and/or low HDL-C [24].  
25  
26  
27  
28  
29  
30

31 DM was the most common metabolic disease in the 21<sup>st</sup> century and approximately 415  
32  
33 million adults were with T2DM worldwide [25]. Prevalence of total diagnosed and  
34  
35 undiagnosed diabetes in China also reached 10.9% in 2013 [26]. What's more, CAD was a  
36  
37 common comorbidity and increased mortality in patients with DM. According to previous  
38  
39 studies, DM patients without angiography-proven CAD showed low risk of MI or CVEs  
40  
41 (defined as death, cardiac death, and MI), but the DM and CAD combination further increased  
42  
43 the risk of ischemic stroke [27-28]. In our previous studies, among patients with established  
44  
45 CAD, individuals with DM were associated with significantly higher risk of worse prognosis  
46  
47 when they were combined with other CAD risk factors, including hypertension and Lp(a)-  
48  
49 hyperlipoproteinemia [14, 29]. Therefore, in the present study, among patients with stable CAD,  
50  
51 identifying whether AD is a risk factor for worse prognosis might be crucial.  
52  
53  
54  
55

56 In strong heart study, high TG plus low HDL levels were associated with a 1.54-fold  
57  
58 greater occurrence risk for CAD and a 2.13-fold occurrence risk for stroke in community based  
59  
60

1  
2  
3 African Americans with DM [8]. In a large cohort of 28,318 DM subjects, increased CAD risk  
4 was observed in both men and women with AD [16]. In the ACCORD trial, for participants  
5 with DM, fenofibrate plus simvastatin 40mg exhibited a 31% reduction in CVEs in the  
6 subgroup with baseline high TG and low HDL-C [9].  
7  
8  
9

10  
11  
12 In fact, more attention has recently been paid to the prevention of DM and the clinical  
13 characters in the early phase of impaired glucose metabolism. Pre-DM was an intermediate  
14 state between NGR and DM and with high predisposition to develop DM. This metabolic  
15 condition was often reversible. The rate of individuals with Pre-DM was almost three times  
16 higher than DM worldwide and in China (35.7% vs.10.9% in China) [25,30]. The prevalence  
17 of Pre-DM and CVEs risk have long been debating. Despite the differences of cut-off point in  
18 diagnose of pre-DM, studies and meta-analysis using blood glucose and HbA1c according to  
19 2003 ADA guideline also had different results [31-32]. In our study population, as previously  
20 reported, the predictive value of Pre-DM for CVEs was less significant, which was also  
21 consistent with studies conducted by Liu et al and Qiu et al [14, 33]. In the present study, 21.8%,  
22 26.6% and 31.2% of patients had AD in NGR, Pre-DM and DM groups. Both Pre-DM and DM  
23 groups had higher rate of AD than NGR group. As the main findings of our study, stable CAD  
24 patients with Pre-DM plus AD had higher GS and increased risk of CVEs while no statistically  
25 significant difference were observed between Pre-DM alone and NGR plus Non-AD groups.  
26 Therefore, similar attention should be given to patients with Pre-DM and DM when they were  
27 with AD.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 The present study had several virtues compared with previous published reports. Very few  
50 studies have evaluated the differences of coronary severity and outcomes according to both  
51 status of glucose metabolism and AD, especially in those with stable CAD. In addition,  
52 previous studies were also limited by the fact that the risk of high TG and/ or low HDL-C levels  
53 were analyzed separately within DM or NGR population, neglecting of the potential high risk  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 which was caused by the interaction of lipid and glucose. Moreover, there were no such studies  
4 about the impacts of AD on cardiovascular outcomes in CAD patients with Pre-DM.  
5  
6 Apparently, a large sample size of angiography-proven CAD patients with high prevalence of  
7  
8 DM and pre-DM were enrolled in the present study. Hard endpoints containing nonfatal strokes,  
9  
10 nonfatal MI, and cardiovascular mortality were also observed during a relatively long follow-  
11  
12 up period. Thereby, our study provided important information regarding dyslipidemia, pre-DM  
13  
14 and outcome, which may influence our treatment decision for CAD patients with pre-DM.  
15  
16  
17  
18

19  
20 Nevertheless, there are still several limitations in the present study. Firstly, this is a single  
21  
22 center study among Chinese patients with stable CAD. Secondly, we measured TG, HDL-C  
23  
24 and glucose metabolism status only at the baseline. The follow-up levels of TG/HDL-C may  
25  
26 also be clinically significant. According to previous study, during the follow-up period, a small  
27  
28 proportion of subjects with Pre-DM may develop DM each year [34]. The increased CAD  
29  
30 severity and CVEs may be overestimated in the Pre-DM group. Thirdly, we did not assess the  
31  
32 all metabolic factors and parameters about insulin resistance due to the features of patients in  
33  
34 our study. Fourthly, although AD plus Pre-DM group did not present increased CVEs risk,  
35  
36 there is possibility that the result missed the statistical significance level due to smaller number  
37  
38 of subjects. Hence, further studies with larger sample size may be needed.  
39  
40  
41  
42

43  
44 In conclusion, in our large sample size with long-term follow-up study, data indicated that  
45  
46 the Pre-DM patients with AD had significantly higher risk of CVEs, suggesting that treatment  
47  
48 and lifestyle management towards AD in Pre-DM patients may also be crucial for improving  
49  
50 clinical outcomes.  
51

## 52 53 54 55 **Contributors**

56  
57 Study concept and design: Professor Jian-Jun-Li, Dr Ying Gao and Dr Jing-Lu Jin. Acquisition  
58  
59 of data: Prof. Jian-Jun-Li, Dr Ye-Xuan Cao and Dr Jing-Lu Jin. Analysis and interpretation of  
60

1  
2  
3 data: Dr Ying Gao and Dr Jing-Lu Jin. Drafting of the manuscript: Dr Jing-Lu Jin. Critical  
4  
5 revision of the manuscript for important intellectual content: Professor Jian-Jun-Li. Statistical  
6  
7 analysis: Dr Jing-Lu Jin. Obtained funding: Professor Jian-Jun-Li and Dr Ying Gao.  
8  
9 Administrative, technical or material support: Drs Li-Guo Wu, Xiang-Dong You, Yuan-Lin  
10  
11 Guo, Na-Qiong Wu, Cheng-Gang Zhu, Hui-Hui Liu, Rui-Xia Xu and Miss Jing Sun and Qian  
12  
13 Dong. Study supervision: Prof Jian-Jun Li.  
14  
15  
16  
17  
18  
19

### 20 **Funding**

21  
22 This work was partially supported by the Capital Health Development Fund (201614035),  
23  
24 CAMS Major Collaborative Innovation Project (2016-I2M-1-011), Fundamental Research  
25  
26 Funds for the Central Universities(2018-F05), and Youth Research Fund of Peking Union  
27  
28 Medical College(2018-XHQN03).  
29  
30  
31  
32  
33

### 34 **Competing interests**

35  
36 None declared  
37  
38  
39  
40  
41

### 42 **Patient consent**

43  
44 Obtained.  
45  
46  
47  
48

### 49 **Ethics approval**

50  
51 The study was performed according to the Declaration of Helsinki, and the hospital ethics  
52  
53 review board (Fuwai Hospital and National Center for Cardiovascular Diseases, Beijing, China)  
54  
55 approved the protocol.  
56  
57  
58  
59  
60

## Data sharing statement

The technical appendix, statistical code and data set are available from the corresponding author.

## References

- [1] Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388:2532–2561.
- [2] Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation* 2007;115:450–458.
- [3] Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. *Nat Rev Genet* 2017;18:331–344.
- [4] Alexander DD, Miller PE, Van Elswyk ME, et al. A Meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. *Mayo Clin Proc* 2017;92:15–29.
- [5] Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol* 2008;51:724–730.
- [6] HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017;377:1217–27.
- [7] Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*. 2015;132:691–718.
- [8] Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. *Diabetes Care*. 2017;40:529-537.



- 1  
2  
3 [9] Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy  
4 in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563–1574  
5  
6  
7 [10] American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes—2018.  
8 *Diabetes Care* 2018;41(Suppl. 1): S55–S64.  
9  
10  
11 [11] Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes  
12 development. *Lancet*. 2012;379:2279–90.  
13  
14  
15 [12] Nam GE, Han K, Kim DH, et al. Relationship between dyslipidemia and albuminuria in prediabetic  
16 adults: the Korea National Health and Nutrition Examination Survey 2011-2012. *Endocrine*. 2015;48:557-  
17 565.  
18  
19  
20 [13] American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes care*.  
21 2011;34(suppl 1):S62–S69.  
22  
23  
24 [14] Liu HH, Cao YX, Li S, et al. Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the  
25 Coronary Severity and Cardiovascular Outcomes. *Hypertension*. 2018;71:1039-1046  
26  
27  
28 [15] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease.  
29 *Am J Cardiol*. 1983;51:606.  
30  
31  
32 [16] Rana JS, Liu JY, Moffet HH, et al. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in  
33 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. *Am J Cardiol*.  
34 2015;116:1700-1704.  
35  
36  
37 [17] Zhao S, Wang Y, Mu Y, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents  
38 in China: results of the DYSlipidemia International Study (DYSIS). *Atherosclerosis*. 2014;235:463-469.  
39  
40  
41 [18] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for  
42 Hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11-22.  
43  
44  
45 [19] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary  
46 events. *N Engl J Med*. 2007;357(21):2109-2122.  
47  
48  
49 [20] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary  
50 syndrome. *N Engl J Med*. 2012;367(22):2089-2099.  
51  
52  
53 [21] Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. *N Engl J Med*.  
54 2017;376(20):1933-1942.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [22] Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. *Circ*  
4 *Res* 2016;118:579–585.  
5  
6  
7 [23] Rana JS, Visser ME, Arsenault B, et al. Metabolic dyslipidemia and risk of future coronary heart disease  
8 in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Int J Cardiol*. 2010  
9 Sep 3;143:399-404.  
10  
11  
12 [24] Adiels M, Olofsson SO, Taskinen MR, Bor'én J. Overproduction of very low-density lipoproteins is  
13 the hallmark of the dyslipidemia in the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008;28:1225–  
14 1236.  
15  
16  
17 [25] Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for  
18 2017 and projections for 2045. *Diabetes Res Clin Pract* 2018;138:271–281.  
19  
20  
21 [26] Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in  
22 2013. *JAMA*. 2017;317(24):2515-2523.  
23  
24  
25 [27] Olesen KKW, Madsen M, Gyldenkerne C, et al. Diabetes Mellitus Is Associated With Increased Risk  
26 of Ischemic Stroke in Patients With and Without Coronary Artery Disease. *Stroke*. 2019;50(12):3347-3354.  
27  
28  
29 [28] Olesen KKW, Madsen M, Egholm G, et al. Patients With Diabetes Without Significant Angiographic  
30 Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a  
31 Real-World Population Receiving Appropriate Prophylactic Treatment. *Diabetes Care*. 2017;40(8):1103-  
32 1110.  
33  
34  
35 [39] Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and Cardiovascular Outcomes in Patients With  
36 Coronary Artery Disease and Prediabetes or Diabetes. *Diabetes Care*. 2019;42(7):1312-1318.  
37  
38  
39 [30] Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the  
40 United States, 1988-2012. *JAMA* 2015;314: 1021–1029.  
41  
42  
43 [31] Laukkanen JA, Mäkikallio TH, Ronkainen K, et al. Impaired fasting plasma glucose and type 2 diabetes  
44 are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. *Diabetes Care*  
45 2013;36:1166-1171.  
46  
47  
48 [32] Rijkkelijkhuizen JM, Nijpels G, Heine RJ, et al. High risk of cardiovascular mortality in individuals with  
49 impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. *Diabetes Care*  
50 2007;30:332-336.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 [33] Qiu M, Shen W, Song X, et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent  
4 occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. *Hypertension*. 2015;65:525–  
5 530.  
6  
7

8  
9 [34] Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with  
10 lifestyle intervention or metformin. *N Engl J Med* 2002;346(6):393-403.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Figure Legends

**Figure 1** Flowchart of the study

**Figure 2** Coronary severity in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia \* for  $p < 0.05$

**Figure 3** Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia

## Tables

**Table 1. Baseline characteristics of the participants according to different glucose metabolism**

	<b>Total n=3057</b>	<b>NGR n=610</b>	<b>Pre-DM n=1370</b>	<b>DM n=1077</b>	<b>P</b>
<b>Clinical factors</b>					
Age, years	58.5±9.8	55.5±10.0	58.8±9.4	59.9±9.8	<0.001
Male, n (%)	2149(70.3)	438(71.8)	956(69.8)	755(70.1)	0.651
BMI (kg/m <sup>2</sup> )	25.6±3.2	25.0±3.0	25.5±3.2	26.1±3.2	<0.001
HT, n (%)	1904(62.3)	339(55.6)	804(58.7)	761(70.7)	<0.001
Family history of CAD	494(16.2)	112(18.4)	221(16.1)	161(14.9)	0.188
Current Smoker, n (%)	1580(51.7)	307(50.3)	714(52.1)	559(51.7)	0.751
Drinking, n (%)	764(25.0)	171(28.0)	333(24.3)	260(24.1)	0.152
Revascularization, n (%)	2182(71.4)	432(70.8)	992(72.4)	758(70.4)	0.514
<b>Laboratory factors</b>					
Glucose (mmol/L)	5.6±1.6	4.7±0.4	5.1±0.6	6.7±2.1	<0.001
HbA1c (%)	6.3±1.1	5.4±0.2	6.0±0.2	7.3±1.2	<0.001
Creatinine (µmol)	73.6±14.1	73.5±14.1	73.3±13.1	74.1±15.2	0.335
hsCRP (µmol/L)	1.5(0.8-2.9)	1.1(0.6-2.2)	1.5(0.8-2.9)	1.7(0.9-3.3)	<0.001
TC (mmol/L)	4.13±1.02	4.00±1.00	4.18±1.00	4.13±1.05	0.001
HDL-C (mmol/L)	1.07±0.28	1.10±0.30	1.09±0.27	1.05±0.27	<0.001
LDL-C (mmol/L)	2.46±0.88	2.37±0.86	2.51±0.87	2.46±0.89	0.003
TG (mmol/L)	1.48(1.09-2.03)	1.38(1.00-1.85)	1.44(1.09-1.98)	1.59(1.17-2.18)	<0.001
LVEF (%)	63.3±7.9	64.0±6.9	63.2±8.4	63.0±7.8	0.026
GS	26(9-44)	24(8-34)	24(8-40)	32(12-56)	<0.001
<b>Prior Medications</b>					
Aspirin, n (%)	2657(86.9)	519(85.1)	1203(87.8)	935(86.8)	0.249
Statins, n (%)	2193(71.7)	423(69.3)	978(71.4)	792(73.5)	0.171
ACEIs/ARBs, n (%)	798(26.1)	149(24.4)	364(26.6)	285(26.5)	0.572
β-blockers, n (%)	1598(52.3)	294(48.2)	721(52.6)	573(53.6)	0.112
<b>Antidiabetic drug</b>					
OADs, n(%)	648(21.2)	-	-	648(60.2)	
Insulin, n(%)	382(12.5)	-	-	382(35.5)	

Data were expressed as mean ± SD, median with 25th and 75th percentile or n (%).

BMI: body mass index; HT: hypertension; CAD: coronary artery disease; HbA1c: haemoglobin A1c; hsCRP: high sensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; LVEF: left ventricular ejection fraction;

1  
2  
3 GS:gensini score; ACEIs: angiotensin-converting enzymes; ARBs: angiotensin receptor blocker; OADs:  
4 oral antidiabetic drug.  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 2. Cox regression models in predicting cardiovascular events according to different glucose metabolism**

Diabetic status (n, events/subjects)	HR (95%CI)		
	Unadjusted model	model 1	model 2
NGR (46/610)	Ref	Ref	Ref
Pre-DM (135/1379)	1.31 (0.94-1.83)	1.29 (0.92-1.81)	1.25 (0.89-1.76)
DM (127/1077)	*1.56 (1.11-2.19)	*1.53 (1.09-2.15)	*1.45 (1.02-2.05)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus;

Model 1 adjusted for age and sex; model 2 adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease, Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitive C-reactive protein, and baseline statins;

**Table 3. Cox Regression Models in Predicting cardiovascular events according to different status of glucose metabolism and atherogenic dyslipidemia**

DM/AD category	Events/Subjects 308/3057	HR (95%CI)	
		Crude Model	Adjusted Model
<b>NGR, Non-AD</b>	31/477	Ref	Ref
<b>Pre-DM, Non-AD</b>	92/1005	1.42 (0.94-2.13)	1.40 (0.92-2.10)
<b>DM, Non-AD</b>	84/741	*1.75 (1.16-2.64)	*1.68 (1.11-2.56)
<b>NGR, AD</b>	15/133	1.74 (0.94-3.22)	1.74 (0.94-3.23)
<b>Pre-DM, AD</b>	43//365	*1.81 (1.14-2.88)	*1.76 (1.10-2.80)
<b>DM, AD</b>	43/336	*1.95(1.23-3.09)	*1.87 (1.17-2.98)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; AD: atherogenic dyslipidemia;

Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease, Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, high sensitive C-reactive protein, and baseline statins;

## Figure legends



1  
2  
3 **Figure 1** Flowchart of the study. CAD, coronary artery disease; ACS, acute coronary syndrome;  
4  
5 CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; NGR:  
6  
7 normal glucose regulation; Pre-DM, pre-diabetes mellitus; DM, diabetes mellitus.  
8  
9

10  
11 **Figure 2** Coronary severity in participants according to **a.** different glucose metabolism; **b.**  
12  
13 different status of glucose metabolism and atherogenic dyslipidemia  
14  
15

16 \* for  $p < 0.05$ ; \*\* for  $p < 0.01$   
17

18 **Figure 3** Kaplan-Meier curves and log-rank tests for cardiovascular events in participants  
19  
20 according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and  
21  
22 atherogenic dyslipidemia  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Flowchart of the study.

188x179mm (300 x 300 DPI)




Figure 2 Coronary severity in participants according to a. different glucose metabolism; b. different status of glucose metabolism and atherogenic dyslipidemia \* for  $p < 0.05$ ; \*\* for  $p < 0.01$

174x269mm (300 x 300 DPI)




Figure 3 Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to a. different glucose metabolism; b. different status of glucose metabolism and atherogenic dyslipidemia

183x250mm (300 x 300 DPI)

## Supplemental Data.

### Supplemental Table S1 Logistic regression analysis regarding the association between glucose metabolism status and high Gensini score (median as cut-off)

DM category	OR (95%CI)	
	Crude Model	Adjusted Model
NGR	Ref	Ref
Pre-DM	1.03 (0.85-1.24)	0.97(0.80-1.18)
DM	*1.55 (1.27-1.90)	*1.42 (1.16-1.75)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease. Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, triglyceride, high density lipoprotein cholesterol, high sensitive C-reactive protein and baseline statins;

**Supplemental Table S2 Logistic regression analysis regarding the association between combined status of glucose metabolism status and atherogenic dyslipidemia and high Gensini Score (median as cut-off)**

DM/AD category	OR (95%CI)	
	Crude Model	Adjusted Model
<b>NGR, Non-AD</b>	Ref	Ref
<b>Pre-DM, Non-AD</b>	0.92 (0.74-1.15)	0.89 (0.71-1.11)
<b>DM, Non-AD</b>	*1.51(1.20-1.90)	*1.43(1.13-1.81)
<b>NGR, AD</b>	1.01(0.69-1.48)	1.01(0.68-1.49)
<b>Pre-DM, AD</b>	*1.39(1.06-1.83)	*1.37(1.04-1.81)
<b>DM, AD</b>	*1.67(1.26-2.21)	*1.64 (1.23-2.19)

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; AD: atherogenic dyslipidemia;

Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease. Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, and high sensitive C-reactive protein, and baseline statins;

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7 7 7 7
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	7 6-7
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6-7 6-7 6-7
Outcome data	15*	Report numbers of outcome events or summary measures over time	7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
2			(b) Report category boundaries when continuous variables were categorized	6-7
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7-8
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9
10				
11	<b>Discussion</b>			
12				
13	Key results	18	Summarise key results with reference to study objectives	9
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
15				
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	10-11
20				
21	<b>Other information</b>			
22				
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
24				
25				

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.



# BMJ Open

## Atherogenic dyslipidemia and cardiovascular events in patients with diabetes or prediabetes and stable coronary artery disease: a prospective, cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037340.R2
Article Type:	Original research
Date Submitted by the Author:	08-Dec-2020
Complete List of Authors:	<p>Jin, Jing-Lu; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Cao, Ye-Xuan; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Wu, Li-Guo; TangXian Peoples Hospital, Hebei Province</p> <p>You, Xiang-Dong; TangXian Peoples Hospital, Hebei Province</p> <p>Guo, Na; TangXian Peoples Hospital, Hebei Province</p> <p>Guo, Yuan-Lin; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Wu, Na-Qiong; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Zhu, Cheng-Gang ; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Xu, Rui-Xia; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Liu, Hui-Hui; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Division of Dyslipidemia</p> <p>Sun, Jing; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Dong, Qian; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Gao, Ying; State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p> <p>Li, Jian-Jun; Chinese Academy of Medical Science, Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>&lt;b&gt;Primary Subject Heading&lt;/b&gt;:</b>	Epidemiology
Secondary Subject Heading:	Nutrition and metabolism
Keywords:	Lipid disorders < DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY, Coronary heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts

BMJ Open: first published as 10.1136/bmjopen-2020-037340 on 17 January 2021. Downloaded from <http://bmjopen.bmj.com/> on April 27, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

**BMJ Open(bmjopen-2020-037340R2)**

**2020-12-20**

**Title:** Atherogenic dyslipidemia and cardiovascular events in patients with diabetes or prediabetes and stable coronary artery disease: a prospective, cohort study

**Running Title:** AD and outcomes in CAD patients with DM or pre-DM

**Authors:** Jing-Lu Jin<sup>1,2</sup>, MD; Ye-Xuan Cao<sup>1</sup>, MD; Li-Guo Wu<sup>3</sup>, MD; Xiang-Dong You<sup>3</sup>, MD; Na Guo<sup>2</sup>, MD; Yuan-Lin Guo<sup>1</sup>, MD; Na-Qiong Wu<sup>1</sup>; MD, Cheng-Gang Zhu<sup>1</sup>; MD, Rui-Xia Xu, PhD; Hui-Hui Liu,<sup>1</sup> MD; Jing Sun<sup>1</sup>, MS; Qian Dong<sup>1</sup>, MS; Ying Gao<sup>1\*</sup>, MD; Jian-Jun Li<sup>1\*</sup>, MD, PhD

**Address:** 1. State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing, 100037, China. 2. Department of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China. 3. TangXian Peoples Hospital, Hebei Province, 072350, China.

**\*Correspondence:** Professor Jian-Jun Li, MD, PhD. **Tel:** 86+10+88396077; **Fax:** 86+10+88396584; **E-mail:** lijianjun938@126.com or Professor Ying Gao, MD.

**E-mail:** cmuxyg@sina.com; BeiLiShi Road 167, Beijing 100037, China.

**ORCID:** 0000-0003-2536-4364

## Abstract

**Objective:** The aim of the study was to investigate the impacts of triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C) dyslipidemia on prognosis in coronary artery disease (CAD) patients with different glucose metabolism status.

**Design:** An observational cohort study

**Setting/Participants:** A total of 3057 patients with stable CAD were consecutively enrolled and divided into 3 groups according to different glucose metabolism status. Atherogenic dyslipidemia (AD) was defined as  $TG \geq 1.7 \text{ mmol/L}$  and  $HDL-C < 1.0 \text{ mmol/L}$  for man or  $< 1.3 \text{ mmol/L}$  for women. The patients were further classified into 6 subgroups by status of AD. All subjects were followed up for the cardiovascular events (CVEs).

**Primary outcome measures:** The primary endpoints were cardiovascular mortality, non-fatal myocardial infarction and non-fatal stroke.

**Results:** During a median follow-up of 6.1 years, 308 (10.1%) CVEs occurred. No significant difference in the occurrence of CVEs was observed between NGR and Pre-DM groups [Hazard Ratio (HR): 1.25, 95% confidence interval (CI): 0.89-1.76] while DM group presented 1.45-fold higher risk of CVEs (HR: 1.45, 95%CI: 1.02-2.05). When the participants were categorized according to combined status of two parameters, the cardiovascular risk was significantly elevated in Pre-DM or DM plus AD group compared with the NGR plus Non-AD group (HR: 1.76, 95%CI: 1.10-2.80 and HR: 1.87, 95%CI: 1.17-2.98).

**Conclusions:** The present study suggested that the presence of AD might affect the prognosis in patients with DM or pre-DM and stable CAD.

**Keywords:** triglyceride, HDL-C, pre-diabetes, prognosis

### Strengths and limitations of this study

- This study fills the gap of the current knowledge on the predictive value of atherogenic dyslipidemia in patients with coronary artery diseases and impaired glucose metabolism.
- The study focuses on hard endpoints during a relatively long follow-up period, which might provide reliable information concerning the impact of dyslipidemia on outcomes in such patients.
- This is a single center, observational study among Chinese patients with stable CAD.
- For inevitable reasons, this study is restricted to the predictive value of baseline parameters.
- More studies may be necessary in different kinds of population such as unstable CAD patients and subjects in randomized clinical trials.

## Introduction

Dyslipidemia is one of the key drivers in atherogenesis. Lipid lowering therapy targeting at low density lipoprotein cholesterol (LDL-C) has been proved to be efficient in secondary prevention of arteriosclerotic cardiovascular disease (ASCVD) [1]. Moreover, strong evidence from epidemiological, genetic and prospective cohort studies verifies that high triglyceride (TG) and/or low levels of high density lipoprotein cholesterol (HDL-C) are associated with cardiovascular disease(CVD)risk [2-4]. It has been demonstrated in large-scale clinical trials that hypertriglyceridemia was associated with increased cardiovascular events (CVEs) [5]. However, clinical trials about therapeutic interventions in patients afflicted with low HDL-C did not show convincing results. Anacetrapib reduced CVEs by 9% in the Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) study but it was not clear whether the risk reduction was attributed to the increase in HDL-C [6]. Type 2 diabetes mellitus (T2DM) is also one of the major risk factors of CVD[7]. Atherogenic dyslipidemia (AD), defined as low HDL-C accompanied with elevated TG, is one of the most important comorbidities in T2DM. Previous studies indicated that individuals with AD presented higher risk of CVD in DM patients [8]. In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, patients with a combination of high baseline TG ( $\geq 204$  mg/dL, highest tertile) and low baseline HDL-C ( $\leq 34$  mg/dL, lowest tertile) showed possible benefit from fenofibrate plus simvastatin therapy compared to simvastatin alone [9]. Standards of medical care in diabetes from American Diabetes Association (ADA) also recommended intensify lifestyle therapy and optimize glycemic control for patients with elevated TG levels and/or low HDL cholesterol [10].

Pre-diabetes (Pre-DM) is an abnormal glucose regulation status with high predisposition to developing T2DM. Pre-DM subjects had similar lipid profile as DM patients. However, the prognosis of Pre-DM patients with coronary artery disease (CAD) was rarely estimated. Also,

1  
2  
3 evidence about whether the Pre-DM alone or accompanied by AD can increase CVD risk in  
4 patients with CAD is lacking. The aim of the study is to test the hypothesis that Pre-DM and  
5  
6 DM plus AD had significant impacts on cardiovascular outcomes in patients with angiography-  
7  
8 proven CAD.  
9  
10  
11  
12  
13  
14

## 15 **Materials and Methods**

### 16 *Study Design and Participants*

17  
18 Our study complied with the Declaration of Helsinki and was approved by the hospital's ethical  
19  
20 review board (Fu Wai Hospital & National Center for Cardiovascular Diseases, Beijing, China).  
21  
22 Informed written consents were obtained from all patients who were enrolled in this study.  
23  
24  
25

26  
27 From March 2011 to November 2013, 4249 consecutive patients were scheduled for  
28  
29 coronary angiography because of clinically suspected CAD. Among these patients, 413 were  
30  
31 excluded because they did not meet the diagnostic criteria of CAD (with a stenosis more than  
32  
33 50% of the at least one major coronary artery). Other exclusion criteria were described in the  
34  
35 flowchart (Fig. 1). As reported in detail previously [11,12], patients were followed up for  
36  
37 primary endpoints which included cardiovascular mortality, non-fatal myocardial infarction  
38  
39 (MI) and stroke.  
40  
41  
42

43  
44 DM and Pre-DM were diagnosed according to according to ADA criteria [13]. Patients  
45  
46 who were without DM or Pre-DM were defined as normal glucose regulation [NGR, fasting  
47  
48 plasma glucose <5.6 and hemoglobin A1c (HbA1c) level <5.7%]. AD was defined as  
49  
50 TG $\geq$ 1.7mmol/L and HDL-C<1.0mmol/L for man or <1.3mmol/L for women. Hypertension  
51  
52 was defined as a self-reported hypertension, currently taking antihypertensive drugs or  
53  
54 recorded systolic blood pressure (SBP)  $\geq$ 140 mmHg and/or diastolic blood pressure (DBP)  $\geq$ 90  
55  
56 mmHg for three or more consecutive times. Information of other disease, family history, and  
57  
58 prior therapy of every patient was also documented.  
59  
60



### ***Laboratory Analysis***

Blood samples were obtained from each patient from the cubital vein after at least 12-h fasting. Concentrations of total cholesterol (TC), TG, LDL-C, HDL-C were measured using automatic biochemistry analyzer (Hitachi 7150, Tokyo, Japan) in an enzymatic assay. The concentrations of glucose were measured by enzymatic hexokinase method. HbA1c was measured using Tosoh Automated Glycohemoglobin Analyser (HLC-723G8, Tokyo, Japan).

### ***Evaluation of Coronary Severity***

Angiographic data were evaluated from catheter laboratory records by 3 experienced interventional cardiologists according to our previous studies [14]. The Gensini score (GS) was calculated as previously described [15].

### ***Statistical Analysis***

The values were expressed as the mean±SD or median (Q1–Q3 quartiles) for the continuous variables and the number (percentage) for the categorical variables. The Kolmogorov–Smirnov test was used to test the distribution pattern. The differences of clinical characteristics between groups were analyzed using the student's t test, analysis of variance, or nonparametric test, chi-squared statistic test or fisher exact test where appropriate. The event-free survival rates among groups were estimated by the Kaplan–Meier method and compared by the log-rank test. Univariate and multivariate Cox regression analyses were performed to calculate the hazard ratios (HRs). Adjust variables were traditional cardiovascular risk factors including age, sex, body mass index (BMI), smoking, hypertension, family history of CAD, GS, left ventricular ejection fraction (LVEF), LDL-C, HDL-C, TG, high sensitive C-reactive protein and baseline statins. A p-value <0.05 was considered statistically significant. The statistical analyses were performed with SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA).

### ***Patient and Public Involvement***

1  
2  
3 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination  
4 plans of our research.  
5  
6  
7  
8  
9

## 10 **Results**

11  
12  
13 As presented in Fig. 1, 20.0%, 44.8%, and 35.2% of 3057 subjects were diagnosed as NGR,  
14 Pre-DM, and DM respectively according to ADA criteria. The baseline characteristics of the  
15 study participants were shown in Table 1. The age, BMI, glucose, HbA1c, TG, and high-  
16 sensitivity C-reactive protein (hsCRP) and proportion of hypertension were elevated from  
17 NGR to DM (all  $P < 0.001$ ). Patients with Pre-DM and DM had elevated levels of TC and LDL-  
18 C than the NGR group. Meanwhile, NGR patients had significantly higher levels of HDL-C  
19 and LVEF than DM population. There was no significant difference regarding other  
20 demographic and laboratory parameters among the three groups ( $p > 0.05$ ).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 The coronary severity was compared among different status of glucose metabolism. As  
33 shown in Fig. 2a and 2b, DM group had significantly higher GS ( $p < 0.05$ ) while there was no  
34 significant difference between Pre-DM and NGR groups ( $P > 0.05$ ). We further divided the  
35 patients into the six groups according to status of glucose metabolism and AD (NGR plus Non-  
36 AD; Pre-DM plus Non-AD; DM plus Non-AD; NGR plus AD; Pre-DM plus AD; DM plus  
37 AD). We set NGR and Non-AD group as reference and compared its GS with that of other  
38 groups. All the other groups had higher GS than the reference group (all  $p < 0.05$ ) except Pre-  
39 DM plus Non-AD and NGR plus AD group ( $p > 0.05$  respectively). As shown in Supplemental  
40 Table S1, multivariate regression logistic regression analysis revealed that DM group was  
41 independently associated with high GS (median as cut-off,  $p < 0.05$ ). Pre-DM plus AD group  
42 and DM plus AD group were also independently associated with the presence of high GS (all  
43  $p < 0.05$ , Supplemental Table S2).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Over a median follow-up time of 6.1 years (5.1 to 7.5 years), 308 CVEs occurred,  
4 including 112 cardiovascular deaths, 73 nonfatal MI and 123 had nonfatal strokes. 7.5%, 9.9%,  
5 and 11.8% of patients had CVEs in NGR, Pre-DM, and DM groups respectively. As indicated  
6 in Kaplan–Meier analysis (Fig. 3a), DM subjects had the highest event rate among the 3 groups  
7 (p<0.05) while there was no significant difference between that of Pre-DM and NGR groups  
8 (p>0.05). However, when the patients were evaluated according to both glucose metabolism  
9 and AD status: DM plus Non-AD, Pre-DM plus AD, and DM plus AD groups had significantly  
10 lower cumulative event-free survival rates compared with the reference group (NGR plus Non-  
11 AD group, Fig. 3b, all p<0.05 respectively). As presented in Table 2, univariate Cox regression  
12 models showed that patients with DM had 1.45-fold higher risk of CVEs than NGR subjects  
13 [HR:1.45, 95% coincidence interval (CI):1.02-2.05, p<0.05]. The Gensini score was also  
14 associated with CVEs [HR:1.004, 95% CI:1.001-1.008, p<0.05]. Additional adjustment for  
15 confounding variables including Gensini score did not change the significance of association.  
16 The presence of Pre-DM did not show increase in CVEs risk when compared with NGR group  
17 (p>0.05). Moreover, multivariate Cox regression analyses according to both glucose  
18 metabolism and AD status indicated that patients in DM plus non-AD, Pre-DM plus AD, and  
19 DM plus AD groups had 1.68-fold (95%CI:1.11-2.56), 1.76-fold (95%CI: 1.10-2.80), and 1.87-  
20 fold (95%CI: 1.17-2.98) higher risk of CVEs (Table 3, all p<0.05 respectively).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

## 50 Discussion

51 The relation of high TG and/or low HDL-C to ASCVD risk has been controversial during the  
52 past decades. Previous prospective studies have shown that patients with high TG combined  
53 with low HDL-C may be more likely to develop ASCVD, especially in those with DM [16]. In  
54 this study, we investigated the impact of AD on cardiovascular outcomes in stable,  
55 angiography-proven CAD patients with different glucose metabolism status. We found that  
56  
57  
58  
59  
60

1  
2  
3 patients with DM but not those with Pre-DM had more severe coronary stenosis and higher  
4 risk of CVEs when the patients were simply divided into the three groups: DM, Pre-DM, and  
5 NGR. Interestingly, when patients were categorized according to both status of glucose  
6 metabolism and AD, individuals with Pre-DM plus AD had higher GS and 1.76-fold increased  
7 risk of CVEs than NGR and Non-AD subjects. Thus, our study suggested that the presence of  
8 AD may have an impact on cardiovascular outcomes in patients with CAD and DM or Pre-  
9 DM.  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 High TG and low HDL-C are common lipid abnormalities among adult population,  
20 especially in Chinese subjects. According to DYSlipidemia International Study (DYSIS), 41.8%  
21 patients had high TG and 31.9% patients had low HDL-C among Chinese population [17].  
22 Additionally, studies about reducing CVD risk by lowering TG and raising HDL-C had  
23 inconsistent results [6,9]. For example, fibrates did not have conclusive effect in ASCVD risk  
24 reduction in ACCORD trials while patients who received 2 g of icosapent ethyl twice daily had  
25 lower risk of ischemic events in Reduction of Cardiovascular Events with Icosapent Ethyl-  
26 Intervention Trial (REDUCE-IT) [9,18]. However, in randomized controlled trials (RCTs),  
27 cholesteryl ester transfer protein (CETP) inhibitors, which could increase plasma HDL-C,  
28 failed to reduce CVEs rates [9, 19-21]. In the meanwhile, Mendelian analysis involving about  
29 20,000 MI individuals and 50,000 controls demonstrated that 1 SD increase in TG levels was  
30 associated with 54% increased risk of MI [22]. In contrast, no such association was found for  
31 patients with low baseline levels of HDL-C [3]. Moreover, in the EPIC-Norfolk prospective  
32 population study, healthy men with AD had 61% higher risk of CAD than those with normal  
33 TG and HDL-C [23]. Of noted, patients who were with obesity, insulin resistance or other  
34 metabolic abnormalities had higher prevalence of high TG and/or low HDL-C [24].  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

56 DM was the most common metabolic disease in the 21<sup>st</sup> century. Approximately 415  
57 million adults were with T2DM worldwide [25]. Prevalence of total diagnosed and  
58  
59  
60

1  
2  
3 undiagnosed diabetes in China reached 10.9% in 2013 [26]. What's more, CAD was a common  
4 comorbidity in patients with DM. According to previous studies, DM patients without  
5 angiography-proven CAD showed low risk of MI or CVEs (defined as death, cardiac death,  
6 and MI), but the DM and CAD combination further increased the risk of ischemic stroke [27-  
7 28]. In our previous studies, among patients with established CAD, individuals with DM were  
8 associated with significantly higher risk of worse prognosis when they were combined with  
9 other CAD risk factors, including hypertension and Lp(a)-hyperlipoproteinemia [14, 29].  
10 Therefore, in the present study, among patients with stable CAD under different glucose  
11 metabolism status, identifying whether AD is a risk factor for worse prognosis might be crucial.  
12 In strong heart study, high TG plus low HDL was associated with a 1.54-fold greater  
13 occurrence risk for CAD and a 2.13-fold occurrence risk for stroke in community based African  
14 Americans with DM [8]. In a large cohort of 28,318 DM subjects, increased CAD risk was  
15 observed in both men and women with AD [16]. In the ACCORD trial, for participants with  
16 DM, fenofibrate plus simvastatin 40mg exhibited a 31% reduction in CVEs in the subgroup  
17 with baseline high TG and low HDL-C [9].

18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38 In fact, more attention has recently been paid to the clinical characters in the early phase  
39 of impaired glucose metabolism for the prevention of DM. Pre-DM was an intermediate state  
40 between NGR and DM and with high predisposition to develop DM. This metabolic condition  
41 was often reversible. The rate of individuals with Pre-DM was almost three times higher than  
42 that of DM worldwide and in China (35.7% vs.10.9% in China) [25,30]. The prevalence of  
43 Pre-DM and CVEs risk have long been debating. There were different cut-off points in the  
44 various definitions to diagnose pre-DM. Studies and meta-analysis using similar blood glucose  
45 and HbA1c cut-offs according to 2003 ADA guideline also had different results [31-32]. In our  
46 study population, as previously reported, the predictive value of Pre-DM for CVEs was less  
47 significant, which was also consistent with studies conducted by Liu et al and Qiu et al [14,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 33]. In the present study, 21.8%, 26.6% and 31.2% of patients had AD in NGR, Pre-DM and  
4  
5 DM groups. Both Pre-DM and DM groups had higher rate of AD than NGR group. As the main  
6  
7 findings of our study, stable CAD patients with Pre-DM plus AD had higher GS and increased  
8  
9 risk of CVEs while no statistically significant difference were observed between Pre-DM plus  
10  
11 Non-AD and NGR plus Non-AD groups. Therefore, similar attention should be given to  
12  
13 patients with Pre-DM and DM when they were with AD.  
14  
15

16  
17 The present study had several virtues compared with previous published reports. Very few  
18  
19 studies have evaluated the differences of coronary severity and outcomes according to both  
20  
21 status of glucose metabolism and AD, especially in those with stable CAD. In addition,  
22  
23 previous studies were also limited by the fact that the risk of high TG and/ or low HDL-C levels  
24  
25 were analyzed separately within DM or NGR population, neglecting of the potential high risk  
26  
27 which was caused by the interaction of lipid and glucose. Moreover, there were no such studies  
28  
29 about the impacts of AD on cardiovascular outcomes in CAD patients with Pre-DM.  
30  
31 Apparently, a large sample size of angiography-proven CAD patients with high prevalence of  
32  
33 DM and pre-DM were enrolled in the present study. Hard endpoints containing nonfatal strokes,  
34  
35 nonfatal MI, and cardiovascular mortality were also observed during a relatively long follow-  
36  
37 up period. Thereby, our study provided important information regarding dyslipidemia, glucose  
38  
39 metabolism status and outcome.  
40  
41  
42  
43  
44

45 Nevertheless, there are still several limitations in the present study. Firstly, this is a single  
46  
47 center study among Chinses patients with stable CAD. Secondly, we measured TG, HDL-C  
48  
49 and glucose metabolism status only at the baseline. The follow-up levels of TG/HDL-C may  
50  
51 also be clinically significant. According to previous study, during the follow-up period, a small  
52  
53 proportion of subjects with Pre-DM may develop DM each year [34]. The increased CAD  
54  
55 severity and CVEs may be overestimated in the Pre-DM group. Thirdly, we did not assess all  
56  
57 metabolic factors and parameters about insulin resistance due to the features of patients in our  
58  
59  
60

1  
2  
3 study. Fourthly, even if AD plus NGR group did not present increased CVEs risk, there is  
4  
5 possibility that the result missed the statistical significance level due to smaller number of  
6  
7 subjects. Hence, further studies with larger sample size may be needed.  
8  
9

10  
11 In conclusion, in our large sample size with long-term follow-up study, data indicated that  
12  
13 the Pre-DM and DM patients with AD had significantly higher risk of CVEs, suggesting that  
14  
15 treatment and lifestyle management towards AD in Pre-DM and DM patients may also be  
16  
17 crucial for improving clinical outcomes.  
18  
19

## 20 21 22 **Contributors**

23  
24 Study concept and design: Professor Jian-Jun-Li, Dr Ying Gao and Dr Jing-Lu Jin. Acquisition  
25  
26 of data: Prof. Jian-Jun-Li, Dr Ye-Xuan Cao and Dr Jing-Lu Jin. Analysis and interpretation of  
27  
28 data: Dr Ying Gao and Dr Jing-Lu Jin. Drafting of the manuscript: Dr Jing-Lu Jin. Critical  
29  
30 revision of the manuscript for important intellectual content: Professor Jian-Jun-Li. Statistical  
31  
32 analysis: Dr Jing-Lu Jin. Obtained funding: Professor Jian-Jun-Li and Dr Ying Gao.  
33  
34 Administrative, technical or material support: Drs Li-Guo Wu, Xiang-Dong You, Yuan-Lin  
35  
36 Guo, Na-Qiong Wu, Cheng-Gang Zhu, Hui-Hui Liu, Rui-Xia Xu and Miss Jing Sun and Qian  
37  
38 Dong. Study supervision: Prof Jian-Jun Li.  
39  
40  
41  
42  
43  
44  
45

## 46 47 **Funding**

48  
49 This work was partially supported by the Capital Health Development Fund (201614035),  
50  
51 CAMS Major Collaborative Innovation Project (2016-I2M-1-011), Fundamental Research  
52  
53 Funds for the Central Universities(2018-F05), and Youth Research Fund of Peking Union  
54  
55 Medical College(2018-XHQ03).  
56  
57  
58  
59  
60

## Competing interests

None declared.

## Patient consent

Obtained.

## Ethics approval

The study was performed according to the Declaration of Helsinki, and the hospital ethics review board (Fuwai Hospital and National Center for Cardiovascular Diseases, Beijing, China) approved the protocol.

## Data sharing statement

The technical appendix, statistical code and data set are available from the corresponding author.

## References

- [1] Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016; 388:2532–2561.
- [2] Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation* 2007;115:450–458.
- [3] Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. *Nat Rev Genet* 2017;18:331–344.



- 1  
2  
3 [4] Alexander DD, Miller PE, Van Elswyk ME, et al. A Meta-analysis of randomized controlled trials and  
4 prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and  
5 coronary heart disease risk. *Mayo Clin Proc* 2017;92:15–29.  
6  
7  
8  
9 [5] Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein  
10 cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol* 2008;51:724–  
11 730.  
12  
13  
14 [6] HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of anacetrapib in  
15 patients with atherosclerotic vascular disease. *N Engl J Med* 2017;377:1217–27.  
16  
17  
18 [7] Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with  
19 type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association  
20 and the American Diabetes Association. *Circulation*. 2015;132:691–718.  
21  
22  
23 [8] Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart  
24 Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study. *Diabetes Care*.  
25 2017;40:529-537.  
26  
27  
28 [9] Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy  
29 in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563–1574  
30  
31  
32 [10] American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes—2018.  
33 *Diabetes Care* 2018;41(Suppl. 1): S55–S64.  
34  
35  
36 [11] Jin JL, Sun D, Cao YX, et al. Triglyceride glucose and haemoglobin glycation index for predicting  
37 outcomes in diabetes patients with new-onset, stable coronary artery disease: a nested case-control study.  
38 *Annals of medicine*. 2018 Oct 3;50(7):576-86.  
39  
40  
41 [12] Jin JL, Cao YX, Liu HH, et al. Impact of free fatty acids on prognosis in coronary artery disease patients  
42 under different glucose metabolism status. *Cardiovascular diabetology*. 2019 Dec 1;18(1):134.  
43  
44  
45 [13] American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes care*.  
46 2011;34(suppl 1):S62–S69.  
47  
48  
49 [14] Liu HH, Cao YX, Li S, et al. Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the  
50 Coronary Severity and Cardiovascular Outcomes. *Hypertension*. 2018;71:1039-1046  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [15] Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease.  
4 Am J Cardiol. 1983;51:606.  
5  
6  
7 [16] Rana JS, Liu JY, Moffet HH, et al. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in  
8 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. Am J Cardiol.  
9 2015;116:1700-1704.  
10  
11  
12 [17] Zhao S, Wang Y, Mu Y, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents  
13 in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235:463-469.  
14  
15  
16 [18] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for  
17 Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.  
18  
19  
20 [19] Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary  
21 events. N Engl J Med. 2007;357(21):2109-2122.  
22  
23  
24 [20] Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary  
25 syndrome. N Engl J Med. 2012;367(22):2089-2099.  
26  
27  
28 [21] Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med.  
29 2017;376(20):1933-1942.  
30  
31  
32 [22] Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ  
33 Res 2016;118:579-585.  
34  
35  
36 [23] Rana JS, Visser ME, Arsenault B, et al. Metabolic dyslipidemia and risk of future coronary heart disease  
37 in apparently healthy men and women: the EPIC-Norfolk prospective population study. Int J Cardiol. 2010  
38 Sep 3;143:399-404.  
39  
40  
41 [24] Adiels M, Olofsson SO, Taskinen MR, Bor'en J. Overproduction of very low-density lipoproteins is  
42 the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:1225-  
43 1236.  
44  
45  
46 [25] Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for  
47 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271-281.  
48  
49  
50 [26] Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in  
51 2013. JAMA. 2017;317(24):2515-2523.  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [27] Olesen KKW, Madsen M, Gyldenkerne C, et al. Diabetes Mellitus Is Associated With Increased Risk  
4 of Ischemic Stroke in Patients With and Without Coronary Artery Disease. *Stroke*. 2019;50(12):3347-3354.  
5  
6 [28] Olesen KKW, Madsen M, Egholm G, et al. Patients With Diabetes Without Significant Angiographic  
7 Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a  
8 Real-World Population Receiving Appropriate Prophylactic Treatment. *Diabetes Care*. 2017;40(8):1103-  
9 1110.  
10  
11 [39] Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and Cardiovascular Outcomes in Patients With  
12 Coronary Artery Disease and Prediabetes or Diabetes. *Diabetes Care*. 2019;42(7):1312-1318.  
13  
14 [30] Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the  
15 United States, 1988-2012. *JAMA* 2015;314: 1021–1029.  
16  
17 [31] Laukkanen JA, Mäkikallio TH, Ronkainen K, et al. Impaired fasting plasma glucose and type 2 diabetes  
18 are related to the risk of out-of-hospital sudden cardiac death and all-cause mortality. *Diabetes Care*  
19 2013;36:1166-1171.  
20  
21 [32] Rijkkelijkhuizen JM, Nijpels G, Heine RJ, et al. High risk of cardiovascular mortality in individuals with  
22 impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. *Diabetes Care*  
23 2007;30:332-336.  
24  
25 [33] Qiu M, Shen W, Song X, et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent  
26 occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. *Hypertension*. 2015;65:525–  
27 530.  
28  
29 [34] Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with  
30 lifestyle intervention or metformin. *N Engl J Med* 2002;346(6):393-403.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Figure Legends

**Figure 1** Flowchart of the study

**Figure 2** Coronary severity in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia \* for  $p < 0.05$

**Figure 3** Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia

## Tables

**Table 1. Baseline characteristics of the participants according to different glucose metabolism**

	<b>Total n=3057</b>	<b>NGR n=610</b>	<b>Pre-DM n=1370</b>	<b>DM n=1077</b>	<b>P</b>
<b>Clinical factors</b>					
Age, years	58.5±9.8	55.5±10.0	58.8±9.4	59.9±9.8	<0.001
Male, n (%)	2149(70.3)	438(71.8)	956(69.8)	755(70.1)	0.651
BMI (kg/m <sup>2</sup> )	25.6±3.2	25.0±3.0	25.5±3.2	26.1±3.2	<0.001
HT, n (%)	1904(62.3)	339(55.6)	804(58.7)	761(70.7)	<0.001
Family history of CAD	494(16.2)	112(18.4)	221(16.1)	161(14.9)	0.188
Current Smoker, n (%)	1580(51.7)	307(50.3)	714(52.1)	559(51.7)	0.751
Drinking, n (%)	764(25.0)	171(28.0)	333(24.3)	260(24.1)	0.152
Revascularization, n (%)	2182(71.4)	432(70.8)	992(72.4)	758(70.4)	0.514
<b>Laboratory factors</b>					
Glucose (mmol/L)	5.6±1.6	4.7±0.4	5.1±0.6	6.7±2.1	<0.001
HbA1c (%)	6.3±1.1	5.4±0.2	6.0±0.2	7.3±1.2	<0.001
Creatinine (µmol)	73.6±14.1	73.5±14.1	73.3±13.1	74.1±15.2	0.335
hsCRP (µmol/L)	1.5(0.8-2.9)	1.1(0.6-2.2)	1.5(0.8-2.9)	1.7(0.9-3.3)	<0.001
TC (mmol/L)	4.13±1.02	4.00±1.00	4.18±1.00	4.13±1.05	0.001
HDL-C (mmol/L)	1.07±0.28	1.10±0.30	1.09±0.27	1.05±0.27	<0.001
LDL-C (mmol/L)	2.46±0.88	2.37±0.86	2.51±0.87	2.46±0.89	0.003
TG (mmol/L)	1.48(1.09-2.03)	1.38(1.00-1.85)	1.44(1.09-1.98)	1.59(1.17-2.18)	<0.001
LVEF (%)	63.3±7.9	64.0±6.9	63.2±8.4	63.0±7.8	0.026
GS	26(9-44)	24(8-34)	24(8-40)	32(12-56)	<0.001
<b>Prior Medications</b>					
Aspirin, n (%)	2657(86.9)	519(85.1)	1203(87.8)	935(86.8)	0.249
Statins, n (%)	2193(71.7)	423(69.3)	978(71.4)	792(73.5)	0.171
ACEIs/ARBs, n (%)	798(26.1)	149(24.4)	364(26.6)	285(26.5)	0.572
β-blockers, n (%)	1598(52.3)	294(48.2)	721(52.6)	573(53.6)	0.112
<b>Antidiabetic drug</b>					
OADs, n(%)	648(21.2)	-	-	648(60.2)	
Insulin, n(%)	382(12.5)	-	-	382(35.5)	

Data were expressed as mean ± SD, median with 25th and 75th percentile or n (%).

BMI: body mass index; HT: hypertension; CAD: coronary artery disease; HbA1c: haemoglobin A1c; hsCRP: high sensitive C-reactive protein; TC: total cholesterol; TG: triglyceride; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; LVEF: left ventricular ejection fraction;

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

GS:gensini score; ACEIs: angiotensin-converting enzymes; ARBs: angiotensin receptor blocker; OADs: oral antidiabetic drug.

For peer review only

**Table 2. Cox regression models in predicting cardiovascular events according to different glucose metabolism**

Diabetic status (n, events/subjects)	HR (95%CI)		
	Unadjusted model	model 1	model 2
<b>NGR (46/610)</b>	Ref	Ref	Ref
<b>Pre-DM (135/1379)</b>	1.31 (0.94-1.83)	1.29 (0.92-1.81)	1.25 (0.89-1.76)
<b>DM (127/1077)</b>	*1.56 (1.11-2.19)	*1.53 (1.09-2.15)	*1.45 (1.02-2.05)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus;

Model 1 adjusted for age and sex; model 2 adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease, Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride, high sensitive C-reactive protein, and baseline statins;

**Table 3. Cox Regression Models in Predicting cardiovascular events according to different status of glucose metabolism and atherogenic dyslipidemia**

DM/AD category	Events/Subjects 308/3057	HR (95%CI)	
		Crude Model	Adjusted Model
<b>NGR, Non-AD</b>	31/477	Ref	Ref
<b>Pre-DM, Non-AD</b>	92/1005	1.42 (0.94-2.13)	1.40 (0.92-2.10)
<b>DM, Non-AD</b>	84/741	*1.75 (1.16-2.64)	*1.68 (1.11-2.56)
<b>NGR, AD</b>	15/133	1.74 (0.94-3.22)	1.74 (0.94-3.23)
<b>Pre-DM, AD</b>	43/365	*1.81 (1.14-2.88)	*1.76 (1.10-2.80)
<b>DM, AD</b>	43/336	*1.95(1.23-3.09)	*1.87 (1.17-2.98)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; AD: atherogenic dyslipidemia;

Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease, Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, high sensitive C-reactive protein, and baseline statins;



## Figure legends

**Figure 1** Flowchart of the study. CAD, coronary artery disease; ACS, acute coronary syndrome; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; NGR: normal glucose regulation; Pre-DM, pre-diabetes mellitus; DM, diabetes mellitus.

**Figure 2** Coronary severity in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia

\* for  $p < 0.05$ ; \*\* for  $p < 0.01$

**Figure 3** Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to **a.** different glucose metabolism; **b.** different status of glucose metabolism and atherogenic dyslipidemia

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Flowchart of the study.

188x179mm (300 x 300 DPI)




Figure 2 Coronary severity in participants according to a. different glucose metabolism; b. different status of glucose metabolism and atherogenic dyslipidemia \* for  $p < 0.05$ ; \*\* for  $p < 0.01$

174x269mm (300 x 300 DPI)




Figure 3 Kaplan-Meier curves and log-rank tests for cardiovascular events in participants according to a. different glucose metabolism; b. different status of glucose metabolism and atherogenic dyslipidemia

183x250mm (300 x 300 DPI)

## Supplemental Data.

### Supplemental Table S1 Logistic regression analysis regarding the association between glucose metabolism status and high Gensini score (median as cut-off)

DM category	OR (95%CI)	
	Crude Model	Adjusted Model
NGR	Ref	Ref
Pre-DM	1.03 (0.85-1.24)	0.97(0.80-1.18)
DM	*1.55 (1.27-1.90)	*1.42 (1.16-1.75)

\* for p<0.05

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease. Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, triglyceride, high density lipoprotein cholesterol, high sensitive C-reactive protein and baseline statins;

**Supplemental Table S2 Logistic regression analysis regarding the association between combined status of glucose metabolism status and atherogenic dyslipidemia and high Gensini Score (median as cut-off)**

DM/AD category	OR (95%CI)	
	Crude Model	Adjusted Model
<b>NGR, Non-AD</b>	Ref	Ref
<b>Pre-DM, Non-AD</b>	0.92 (0.74-1.15)	0.89 (0.71-1.11)
<b>DM, Non-AD</b>	*1.51(1.20-1.90)	*1.43(1.13-1.81)
<b>NGR, AD</b>	1.01(0.69-1.48)	1.01(0.68-1.49)
<b>Pre-DM, AD</b>	*1.39(1.06-1.83)	*1.37(1.04-1.81)
<b>DM, AD</b>	*1.67(1.26-2.21)	*1.64 (1.23-2.19)

NGR: normal glucose regulation; Pre-DM: pre-diabetes mellitus; DM: diabetes mellitus; AD: atherogenic dyslipidemia;

Model adjusted for age, sex, body mass index, smoking, hypertension, family history of coronary artery disease. Gensini score, left ventricular ejection fraction, low density lipoprotein cholesterol, and high sensitive C-reactive protein, and baseline statins;

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	7 7 7 7
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	7 6-7
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	6-7 6-7 6-7
Outcome data	15*	Report numbers of outcome events or summary measures over time	7

1	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	7
2			(b) Report category boundaries when continuous variables were categorized	6-7
3			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	7-8
4				
5				
6				
7				
8				
9	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	8-9
10				
11	<b>Discussion</b>			
12				
13	Key results	18	Summarise key results with reference to study objectives	9
14	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
15				
16				
17	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
18				
19	Generalisability	21	Discuss the generalisability (external validity) of the study results	10-11
20				
21	<b>Other information</b>			
22				
23	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	13
24				
25				

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.